<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006377.pub3" GROUP_ID="GYNAECA" ID="430505071214181444" MERGED_FROM="" MODIFIED="2015-11-26 13:20:34 +0000" MODIFIED_BY="Clare Jess" NOTES="&lt;p&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.2&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2015-11-26 13:11:16 +0000" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="J011" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.3">
<COVER_SHEET MODIFIED="2015-11-26 13:20:34 +0000" MODIFIED_BY="Clare Jess">
<TITLE MODIFIED="2010-01-28 13:19:43 +0000" MODIFIED_BY="Gail Quinn">Combined use of hyperthermia and radiation therapy for treating locally advanced cervix carcinoma</TITLE>
<CONTACT MODIFIED="2015-11-26 13:20:34 +0000" MODIFIED_BY="Clare Jess"><PERSON ID="DD1600F582E26AA201E74FE97E9BE68B" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Ludy</FIRST_NAME><LAST_NAME>Lutgens</LAST_NAME><SUFFIX>MD, PhD</SUFFIX><POSITION>Radiation Oncologist</POSITION><EMAIL_1>ludy.lutgens@maastro.nl</EMAIL_1><ADDRESS><DEPARTMENT>Radiation Oncology</DEPARTMENT><ORGANISATION>Maastro Clinic</ORGANISATION><ADDRESS_1>Dr. Tanslaan 12, 6229 ET Maastricht</ADDRESS_1><ADDRESS_2>Postbus 5800</ADDRESS_2><CITY>Maastricht</CITY><ZIP>6202 AZ</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>0031-88 - 556 66 66</PHONE_1><FAX_1>0031-88 - 556 66 67</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2015-11-26 13:20:34 +0000" MODIFIED_BY="Clare Jess"><PERSON ID="DD1600F582E26AA201E74FE97E9BE68B" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Ludy</FIRST_NAME><LAST_NAME>Lutgens</LAST_NAME><SUFFIX>MD, PhD</SUFFIX><POSITION>Radiation Oncologist</POSITION><EMAIL_1>ludy.lutgens@maastro.nl</EMAIL_1><ADDRESS><DEPARTMENT>Radiation Oncology</DEPARTMENT><ORGANISATION>Maastro Clinic</ORGANISATION><ADDRESS_1>Dr. Tanslaan 12, 6229 ET Maastricht</ADDRESS_1><ADDRESS_2>Postbus 5800</ADDRESS_2><CITY>Maastricht</CITY><ZIP>6202 AZ</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>0031-88 - 556 66 66</PHONE_1><FAX_1>0031-88 - 556 66 67</FAX_1></ADDRESS></PERSON><PERSON ID="DD15FF7E82E26AA201E74FE9118E6174" ROLE="AUTHOR"><FIRST_NAME>Jacoba</FIRST_NAME><LAST_NAME>van der Zee</LAST_NAME><POSITION>Radiation Oncologist</POSITION><ADDRESS><DEPARTMENT>Department of Radiation Oncology</DEPARTMENT><ORGANISATION>Erasmus Medical Center</ORGANISATION><ADDRESS_1>PO Box 2040</ADDRESS_1><CITY>Rotterdam</CITY><ZIP>3000 CA</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 10 439 1263</PHONE_1><FAX_1>+31 10 439 1011</FAX_1></ADDRESS></PERSON><PERSON ID="9506FD8982E26AA20088EE033571EAC6" ROLE="AUTHOR"><FIRST_NAME>Madelon</FIRST_NAME><LAST_NAME>Pijls-Johannesma</LAST_NAME><POSITION>Researcher</POSITION><EMAIL_1>madelon.pijls@maastro.nl</EMAIL_1><URL>http://www.maastro.com</URL><ADDRESS><DEPARTMENT>Department of Radiation Oncology (MAASTRO)</DEPARTMENT><ORGANISATION>GROW-School for Oncology and Developmental Biology</ORGANISATION><ADDRESS_1>Maastricht University Medical Centre</ADDRESS_1><CITY>Maastricht</CITY><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 88 4455666</PHONE_1><FAX_1>+31 88 4455667</FAX_1></ADDRESS></PERSON><PERSON ID="3637681E82E26AA200D5E26BF1F8D39C" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Danielle</FIRST_NAME><MIDDLE_INITIALS>FM</MIDDLE_INITIALS><LAST_NAME>De Haas-Kock</LAST_NAME><SUFFIX>MD</SUFFIX><POSITION>Radiation Oncologist</POSITION><EMAIL_1>danielle.dehaas@maastro.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Radiation Oncology (MAASTRO clinic)</DEPARTMENT><ORGANISATION>GROW Research Institute, University Medical Center</ORGANISATION><ADDRESS_1>dr. Tanslaan 12</ADDRESS_1><CITY>Maastricht</CITY><ZIP>6229 ET</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>0031 43  3874461</PHONE_1></ADDRESS></PERSON><PERSON ID="85BB75F682E26AA20091CCEB2DC4C81C" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Jeroen</FIRST_NAME><LAST_NAME>Buijsen</LAST_NAME><POSITION>Radiation Oncologist</POSITION><EMAIL_1>jeroen.buijsen@maastro.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Radiation Oncology (MAASTRO clinic)</DEPARTMENT><ORGANISATION>GROW Research Institute, University Medical Center</ORGANISATION><ADDRESS_1>dr. Tanslaan 12</ADDRESS_1><CITY>Maastricht</CITY><ZIP>6229 ET</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY></ADDRESS></PERSON><PERSON ID="B03709D582E26AA200AED5649A6E2160" ROLE="AUTHOR"><FIRST_NAME>Ghislaine</FIRST_NAME><MIDDLE_INITIALS>APG</MIDDLE_INITIALS><LAST_NAME>van Mastrigt</LAST_NAME><POSITION>MD</POSITION><ADDRESS><DEPARTMENT>Department of Radiation Oncology (MAASTRO)</DEPARTMENT><ORGANISATION>GROW - School for Oncology and Developmental Biology</ORGANISATION><ADDRESS_1>Maastricht University Medical Centre</ADDRESS_1><CITY>Maastricht</CITY><COUNTRY CODE="NL">Netherlands</COUNTRY></ADDRESS></PERSON><PERSON ID="D659256D82E26AA200831C192BA8F263" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Guido</FIRST_NAME><LAST_NAME>Lammering</LAST_NAME><SUFFIX>MD PhD</SUFFIX><POSITION>Radiation Oncologist</POSITION><EMAIL_1>guido.lammering@maastro.nl</EMAIL_1><ADDRESS><DEPARTMENT>Radiation Oncology</DEPARTMENT><ORGANISATION>Maastro Clinic</ORGANISATION><ADDRESS_1>Dr. Tanslaan 12, 6229 ET Maastricht</ADDRESS_1><ADDRESS_2>Postbus 5800</ADDRESS_2><CITY>Maastricht</CITY><ZIP>6202 AZ</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 88 5566666</PHONE_1><FAX_1>+31 88 5566667</FAX_1></ADDRESS></PERSON><PERSON ID="17060" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Dirk</FIRST_NAME><MIDDLE_INITIALS>K M</MIDDLE_INITIALS><LAST_NAME>De Ruysscher</LAST_NAME><SUFFIX>MD, Ph.D</SUFFIX><EMAIL_1>dirk.deruysscher@uzleuven.be</EMAIL_1><URL>http.//www.maastro.com</URL><ADDRESS><DEPARTMENT>Department of Radiation Oncology</DEPARTMENT><ORGANISATION/><ADDRESS_1>University Hospital Leuven</ADDRESS_1><CITY>Leuven</CITY><COUNTRY CODE="BE">Belgium</COUNTRY><PHONE_1>0031 88 44 55666</PHONE_1><FAX_1>0031 88 44 55667</FAX_1></ADDRESS></PERSON><PERSON ID="17061" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Philippe</FIRST_NAME><LAST_NAME>Lambin</LAST_NAME><SUFFIX>MD, Ph.D</SUFFIX><POSITION>Medical Director</POSITION><EMAIL_1>Philippe.Lambin@maastro.nl</EMAIL_1><URL>http.//www.maastro.com</URL><ADDRESS><DEPARTMENT>Department of Radiation Oncology (MAASTRO)</DEPARTMENT><ORGANISATION>GROW-School for Oncology and Developmental Biology</ORGANISATION><ADDRESS_1>Maastricht University Medical Centre</ADDRESS_1><CITY>Maastricht</CITY><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>0031 88 44 55666</PHONE_1><FAX_1>0031 88 44 55667</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2015-11-26 13:05:23 +0000" MODIFIED_BY="Clare Jess">
<UP_TO_DATE>
<DATE DAY="28" MONTH="1" YEAR="2010"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="5" MONTH="1" YEAR="2009"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="10" MONTH="11" YEAR="2011"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2010"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2010"/>
</DATES>
<WHATS_NEW MODIFIED="2015-11-26 13:11:16 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2015-11-26 13:11:16 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="26" MONTH="11" YEAR="2015"/>
<DESCRIPTION>
<P>Feedback and author's response added to the review</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2015-11-26 13:10:47 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2015-11-26 13:10:47 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="22" MONTH="1" YEAR="2010"/>
<DESCRIPTION>
<P>Revisions incorporated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="24" MONTH="7" YEAR="2008"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2009-11-10 13:39:21 +0000" MODIFIED_BY="Gail Quinn">
<INTERNAL_SOURCES MODIFIED="2009-11-10 13:39:21 +0000" MODIFIED_BY="Gail Quinn">
<SOURCE MODIFIED="2009-11-10 13:39:21 +0000" MODIFIED_BY="Gail Quinn">
<NAME>New Source of support</NAME>
<COUNTRY CODE="NONE">Other</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2010-02-01 14:02:50 +0000" MODIFIED_BY="Gail Quinn">
<SUMMARY MODIFIED="2010-02-01 14:01:41 +0000" MODIFIED_BY="Gail Quinn">
<TITLE MODIFIED="2010-01-28 13:19:44 +0000" MODIFIED_BY="Gail Quinn">Combined use of hyperthermia and radiation therapy for treating locally advanced cervix carcinoma</TITLE>
<SUMMARY_BODY MODIFIED="2010-02-01 14:01:41 +0000" MODIFIED_BY="Gail Quinn">
<P>Cure of cervix carcinomas can be achieved by complete surgical removal of the tumour or destruction of the tumour or by means of radiation. If the tumour has grown beyond the boundaries of the cervix or has reached a size larger than 4 cm in diameter it is designated as locally advanced cervix carcinoma. For such tumours surgery alone is considered insufficient and radiotherapy will be chosen instead. However, the larger the tumour, the smaller the chance that radiotherapy alone will be able to cure the tumour. In several clinical studies it was found that the respons of these tumours to radiotherapy was improved by adding hyperthermia. Hyperthermia is a type of cancer treatment in which body tissue is exposed to high temperatures (i.e. around 42 to 43 degrees Celcius during one hour) to damage and kill cancer cells.. This temperature is in itself able to kill tumour cells under certain conditions and also increases the lethal effect of radiation on tumour cells. can However, the results observed with this treatment were not consistent in subsequent clinical studies. Therefore we analysed the results of all clinical studies published so far comparing the treatment results of radiotherapy alone with the results of combined radiotherapy and hyperthermia in patients with locally advanced cervix carcinoma. The results do suggest a better outcome for patients treated with the combination of radiotherapy with hyperthermia. Thus following treatment a complete disappearance of the tumour was observed more regularly, regrowth of the tumour at the site of origin during follow up was observed less frequently and more patients were still alive at last follow-up. Treatment related side effects were not increased by the addition of hyperthermia to standard radiotherapy. However, the number of patients included in the clinical studies analysed is limited as the majority of patients had stage IIIB disease. The authors therefore conclude that hyperthermia may provide a clinically relevant improvement in treatment outcome for patients with locally advanced cervix carcinoma, in particular patients with stage IIIB disease. Additional clinical data are needed to warrant its use for all patients with locally advanced cervix carcinoma.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2010-01-28 13:19:44 +0000" MODIFIED_BY="Gail Quinn">
<ABS_BACKGROUND MODIFIED="2010-01-28 13:19:44 +0000" MODIFIED_BY="Gail Quinn">
<P>Hyperthermia is a type of cancer treatment in which body tissue is exposed to high temperatures to damage and kill cancer cells. It was introduced into clinical oncology practice several decades ago. Positive clinical results, mostly obtained in single institutions, resulted in clinical implementation albeit in a limited number of cancer centres worldwide. Because large scale randomised clinical trials (RCTs) are lacking, firm conclusions cannot be drawn regarding its definitive role as an adjunct to radiotherapy in the treatment of locally advanced cervix carcinoma (LACC).<B>
<BR/>
</B>
</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2009-10-28 14:59:04 +0000" MODIFIED_BY="Gail Quinn">
<P>To assess whether adding hyperthermia to standard radiotherapy for LACC has an impact on (1) local tumour control, (2) survival and (3) treatment related morbidity.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2009-10-28 12:01:23 +0000" MODIFIED_BY="Gail Quinn">
<P>The electronic databases of the Cochrane Central Register of Controlled Trials (CENTRAL), (Issue 1, 2009) and Cochrane Gynaecological Cancer Groups Specialised Register, MEDLINE, EMBASE, online databases for trial registration, handsearching of journals and conference abstracts, reviews, reference lists, and contacts with experts were used to identify potentially eligible trials, published and unpublished until January 2009.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2009-10-05 15:38:25 +0100" MODIFIED_BY="[Empty name]">
<P>RCTs comparing radiotherapy alone (RT) versus combined hyperthermia and radiotherapy (RHT) in patients with LACC.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2009-10-28 12:33:46 +0000" MODIFIED_BY="Gail Quinn">
<P>Between 1987 and 2009 the results of six RCTs were published, these were used for the current analysis. </P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2010-01-28 13:19:44 +0000" MODIFIED_BY="Gail Quinn">
<P>74% of patients had FIGO stage IIIB LACC. Treatment outcome was significantly better for patients receiving the combined treatment (Figures 4 to 6). The pooled data analysis yielded a significantly higher complete response rate (relative risk (RR) 0.56; 95% confidence interval (CI) 0.39 to 0.79; p &lt; 0.001), a significantly reduced local recurrence rate (hazard ratio (HR) 0.48; 95% CI 0.37 to 0.63; p &lt; 0.001) and a significantly better overall survival (OS) following the combined treatment with RHT(HR 0.67; 95% CI 0.45 to 0.99; p = 0.05). No significant difference was observed in treatment related acute (RR 0.99; 95% CI 0.30 to 3.31; p = 0.99) or late grade 3 to 4 toxicity (RR 1.01; CI 95% 0.44 to 2.30; p = 0.96) between both treatments.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2010-01-28 13:19:44 +0000" MODIFIED_BY="Gail Quinn">
<P>The limited number of patients available for analysis, methodological flaws and a significant over-representation of patients with FIGO stage IIIB prohibit drawing definite conclusions regarding the impact of adding hyperthermia to standard radiotherapy. However, available data do suggest that the addition of hyperthermia improves local tumour control and overall survival in patients with locally advanced cervix carcinoma without affecting treatment related grade 3 to 4 acute or late toxicity.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2010-02-01 14:02:50 +0000" MODIFIED_BY="Gail Quinn">
<BACKGROUND MODIFIED="2010-01-28 13:19:44 +0000" MODIFIED_BY="Gail Quinn">
<CONDITION MODIFIED="2009-10-20 20:37:52 +0100" MODIFIED_BY="[Empty name]">
<P>For many years radiotherapy alone has been the treatment of choice in patients with LACC. Spread to the para-aortic lymph nodes has been recognised as the single most important prognostic factor (<LINK REF="REF-Fyles-1995" TYPE="REFERENCE">Fyles 1995</LINK>; <LINK REF="REF-Stehman-1991" TYPE="REFERENCE">Stehman 1991</LINK>). Nevertheless pelvic tumour control is a pre-requisite for cure (<LINK REF="REF-Haie-1988" TYPE="REFERENCE">Haie 1988</LINK>; <LINK REF="REF-Rotman-1995" TYPE="REFERENCE">Rotman 1995</LINK>). Perez et al reported overall pelvic recurrences in 14%, 41%, 41% and 72%, whereas distant recurrences only were found in 12%, 18%, 16% and 21% of 1499 patients with FIGO stage I, II, III and IVA disease treated with radiotherapy (<LINK REF="REF-Perez-1998" TYPE="REFERENCE">Perez 1998</LINK>). Similarly, Horiot et al reported pelvic recurrences in 6%,17%,43% and 56% of 1383 patients with stage I, II, III and IVA, respectively, treated with radiotherapy (<LINK REF="REF-Horiot-1988" TYPE="REFERENCE">Horiot 1988</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2010-01-28 13:19:44 +0000" MODIFIED_BY="Gail Quinn">
<P>Since 1987 the results of six randomised clinical trials (RCTs) have been published concerning the combined treatment of radiotherapy with hyperthermia (RHT) in patients with cervix carcinoma (<LINK REF="STD-Chen-1997" TYPE="STUDY">Chen 1997</LINK>; <LINK REF="STD-Datta-1987" TYPE="STUDY">Datta 1987</LINK>; <LINK REF="STD-Harima-2001" TYPE="STUDY">Harima 2001</LINK>; <LINK REF="STD-Sharma-1991" TYPE="STUDY">Sharma 1991</LINK>; <LINK REF="STD-van-der-Zee-2000" TYPE="STUDY">van der Zee 2000</LINK>; <LINK REF="STD-Vasanthan-2005" TYPE="STUDY">Vasanthan 2005</LINK>). Local tumour control and overall survival appeared to be improved by the addition of hyperthermia, although clinical observations were not unanimous. Possible explanations for the discrepancy may be found in the patient selection (e.g. with respect to stage or tumour volume) and other confounding factors such as treatment parameters (e.g. overall treatment time and hyperthermia technique). Therefore, the magnitude of any beneficial effect as well as the proper selection of patients for any combined treatment remains to be demonstrated.</P>
</INTERVENTION>
<THEORY MODIFIED="2010-01-28 13:19:44 +0000" MODIFIED_BY="Gail Quinn">
<P>In LACC the pelvis is the most common site of failure after treatment with radiotherapy. Several tumour characteristics have been related to the risk of pelvic failure following radiotherapy (<LINK REF="REF-Eifel-1994" TYPE="REFERENCE">Eifel 1994</LINK>; <LINK REF="REF-Fyles-1995" TYPE="REFERENCE">Fyles 1995</LINK>; <LINK REF="REF-Haensgen-2001" TYPE="REFERENCE">Haensgen 2001</LINK>; <LINK REF="REF-Hockel-1993" TYPE="REFERENCE">Hockel 1993</LINK>; <LINK REF="REF-Horiot-1988" TYPE="REFERENCE">Horiot 1988</LINK>; <LINK REF="REF-Lanciano-1991" TYPE="REFERENCE">Lanciano 1991</LINK>; <LINK REF="REF-Mendenhall-1984" TYPE="REFERENCE">Mendenhall 1984</LINK>; <LINK REF="REF-Perez-1998" TYPE="REFERENCE">Perez 1998</LINK>; <LINK REF="REF-Stehman-1991" TYPE="REFERENCE">Stehman 1991</LINK>; <LINK REF="REF-Stehman-1994" TYPE="REFERENCE">Stehman 1994</LINK>; <LINK REF="REF-Thomas-2001" TYPE="REFERENCE">Thomas 2001</LINK>; <LINK REF="REF-Tsang-1995" TYPE="REFERENCE">Tsang 1995</LINK>; <LINK REF="REF-Werner-1995" TYPE="REFERENCE">Werner 1995</LINK>; <LINK REF="REF-West-1995" TYPE="REFERENCE">West 1995</LINK>). Probably the single most important of these is tumour volume (<LINK REF="REF-Fyles-1995" TYPE="REFERENCE">Fyles 1995</LINK>; <LINK REF="REF-Perez-1998" TYPE="REFERENCE">Perez 1998</LINK>; <LINK REF="REF-Tsang-1995" TYPE="REFERENCE">Tsang 1995</LINK>). Although tumour hypoxia is suggested to be an independent prognostic factor by some (<LINK REF="REF-Hockel-1999" TYPE="REFERENCE">Hockel 1999</LINK>; <LINK REF="REF-Vaupel-2001" TYPE="REFERENCE">Vaupel 2001</LINK>) both animal (<LINK REF="REF-De-Jaeger-1998" TYPE="REFERENCE">De Jaeger 1998</LINK>; <LINK REF="REF-Khalil-1995" TYPE="REFERENCE">Khalil 1995</LINK>; <LINK REF="REF-Milross-1997" TYPE="REFERENCE">Milross 1997</LINK>) and human data (<LINK REF="REF-Fyles-1998" TYPE="REFERENCE">Fyles 1998</LINK>) have demonstrated an association between tumour volume and tumour hypoxia. Thus with increasing tumour volume, tumour necrosis increases and as a result oxygenation status worsens (<LINK REF="REF-De-Jaeger-1998" TYPE="REFERENCE">De Jaeger 1998</LINK>; <LINK REF="REF-Khalil-1995" TYPE="REFERENCE">Khalil 1995</LINK>; <LINK REF="REF-Milross-1997" TYPE="REFERENCE">Milross 1997</LINK>). Anaerobic glycolysis will thus increase and consequently tissue pH will decrease. At acid pH cells become more sensitive to hyperthermia whereas under these hypoxic conditions cells will be less sensitive to radiotherapy. It's under these circumstances that a therapeutic gain of hyperthermia is to be expected. In addition to a direct cytotoxic effect of hyperthermia radiation-induced DNA damage repair is inhibited by hyperthermia. Indirectly radiosensitivity will improve as tumour blood flow will increase thus improving tumour oxygenation. </P>
</THEORY>
<IMPORTANCE MODIFIED="2010-01-28 13:19:44 +0000" MODIFIED_BY="Gail Quinn">
<P>The potential benefit of combining hyperthermia with radiotherapy in cervix carcinomas was established several decades ago (<LINK REF="REF-Brady-1976" TYPE="REFERENCE">Brady 1976</LINK>), but RCTs are scarce. Furthermore, the number of patients included in the few available RCTs is small and are inconsistent regarding the beneficial effect of hyperthermia (<LINK REF="STD-Harima-2001" TYPE="STUDY">Harima 2001</LINK>; <LINK REF="STD-van-der-Zee-2000" TYPE="STUDY">van der Zee 2000</LINK>; <LINK REF="STD-Vasanthan-2005" TYPE="STUDY">Vasanthan 2005</LINK>). Of importance also are the fundamental differences that exist in the heating techniques used, thus prohibiting any firm conclusion regarding the therapeutic benefit. The majority of published data deal with technical developments and do not provide treatment results. Despite these drawbacks, however, overall clinical data on the combined use of radiotherapy and hyperthermia suggest a therapeutic gain as compared to single modality treatment (<LINK REF="REF-Dinges-1998" TYPE="REFERENCE">Dinges 1998</LINK>; <LINK REF="STD-Harima-2001" TYPE="STUDY">Harima 2001</LINK>; <LINK REF="STD-Hornback-1986" TYPE="STUDY">Hornback 1986</LINK>;; <LINK REF="STD-van-der-Zee-2000" TYPE="STUDY">van der Zee 2000</LINK>; <LINK REF="STD-Vasanthan-2005" TYPE="STUDY">Vasanthan 2005</LINK>). Therefore a systematic analysis on this treatment modality is required.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2009-10-05 15:38:26 +0100" MODIFIED_BY="[Empty name]">
<P>This systematic review aims to provide a comprehensive and reliable summary of the effect of hyperthermia on LACC when applied concomitantly with radiotherapy. The specific aim is to review all prospective RCTs (phase II and phase III) which compare the effectiveness of combined hyperthermia and radiotherapy (RHT) with radiotherapy alone (RT) in patients treated for LACC.</P>
</OBJECTIVES>
<METHODS MODIFIED="2010-01-28 13:19:44 +0000" MODIFIED_BY="Gail Quinn">
<SELECTION_CRITERIA MODIFIED="2010-01-28 13:19:44 +0000" MODIFIED_BY="Gail Quinn">
<CRIT_STUDIES MODIFIED="2009-10-28 12:57:19 +0000" MODIFIED_BY="Gail Quinn">
<P>RCTs (phase II or III). </P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2009-03-27 15:16:54 +0000" MODIFIED_BY="Clare Jess">
<P>Patients of any age with histologically proven LACC and with a WHO performance status 0 to 2 (<LINK REF="REF-WHO-1979" TYPE="REFERENCE">WHO 1979</LINK>). Cervical cancers with a central diameter equal or larger than 4 cm and/or FIGO stage IIB to IVA are considered locally advanced. Studies with less than 20 patients were excluded.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2009-10-28 12:57:44 +0000" MODIFIED_BY="Gail Quinn">
<P>Any regimen of radiotherapy for uterine cervical carcinoma consisting of (generally considered) curative doses of external beam radiotherapy (EBRT) with or without brachytherapy (BCT) given concurrently or not with hyperthermia. Only studies which used a minimum temperature of 40<SUP>o</SUP> celsius for hyperthermia were included. In case of concomitant use of chemotherapy and radiotherapy studies were included when hyperthermia was the only treatment variable. In that case no further distinction was made between different chemotherapy schedules.</P>
<P>Studies in which it was not possible to separate data on patients receiving combined hyperthermia plus radiotherapy (RHT) versus radiotherapy alone (RT), even after contacting the authors, were excluded.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2010-01-28 13:19:44 +0000" MODIFIED_BY="Gail Quinn">
<P>The following clinically relevant outcomes were studied:</P>
<UL>
<LI>Complete tumour response (CR) at two months (that is no evidence of disease as assessed with clinical examination and/or any imaging technique).In cervical carcinoma a CR following radiotherapy is predictive for a durable pelvic tumour control.</LI>
<LI>Local tumour recurrence (LR) </LI>
<LI>Overall Survival (OS) </LI>
<LI>Grade 3 to 4 acute toxicity (Tox acute; i.e. treatment related toxicity occurring during and/or lasting up to six weeks following treatment) and grade 3 to 4 late toxicity (Tox late; i.e. treatment related toxicity lasting or occurring more than six months after treatment).</LI>
</UL>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2009-11-10 13:40:59 +0000" MODIFIED_BY="Gail Quinn">
<ELECTRONIC_SEARCHES MODIFIED="2009-11-10 13:40:59 +0000" MODIFIED_BY="Gail Quinn">
<P>For this review we identified the relevant trials in any language through electronic searches of the following databases:</P>
<UL>
<LI>Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 1, 2009)</LI>
<LI>Cochrane Gynaecological Cancer Groups Specialised Register (beginning to present)</LI>
<LI>MEDLINE (1966 to present)</LI>
<LI>EMBASE (1974 to present)</LI>
<LI>CINAHL (1982 to present)</LI>
</UL>
<P>Furthermore, various trial databases were searched for the identification of recent completed and ongoing trials (metaRegister of Controlled Trials, Cancer Research UK, Cancer.gov, The Eastern Cooperative Oncology Group Trials Database). All studies identified until January 2009 were included in the present study.</P>
<P>For search strategies used see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>, <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK> and <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>
</P>
<P>Search strategies have been developed and executed by the author team.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-11-12 13:49:15 +0000" MODIFIED_BY="Clare Jess">
<P>Handsearching was performed in the following journals; International Journal of Radiation, Oncology, Biology and Physics,Radiotherapy and Oncology; Journal of Clinical Oncology; Clinical Oncology and the International Journal of Hyperthermia. In addition, published abstracts of the ASTRO, ESTRO and ESHO conference proceedings of the last three years were screened. We scrutinised reference lists from identified studies and reviews for additional studies. Colleagues, collaborators and other experts in the field were asked to identify missing and unreported trials.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2010-01-28 13:19:44 +0000" MODIFIED_BY="Gail Quinn">
<STUDY_SELECTION MODIFIED="2009-10-28 12:58:54 +0000" MODIFIED_BY="Gail Quinn">
<P>All titles and abstracts of reports identified by electronic searches or handsearching were assessed to determine if they meet the eligibility criteria by three independent review authors (CVZ, DDH, LL). In a consensus meeting (DDH, GVM, JB, LL) discrepancies were discussed. Furthermore, if necessary the full journal papers were screened to identify study characteristics.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2010-01-28 13:19:44 +0000" MODIFIED_BY="Gail Quinn">
<P>Two review authors (DDH, LL) screened the included studies for methodological quality according to pre-determined criteria (<LINK TAG="QUALITY_ASSESSMENT" TYPE="SECTION">Assessment of risk of bias in included studies</LINK>), the treatment characteristics (radiotherapy, hyperthermia, chemotherapy) and the results of outcome measures (<LINK TAG="CRIT_OUTCOMES" TYPE="SECTION">Types of outcome measures</LINK>). For time to event (OS or local tumour recurrence) data, we extracted the log of the hazard ratio [log(HR)] and its standard error from trial reports; if these were not reported, we estimated them from other reported statistics using the methods of <LINK REF="REF-Parmar-1998" TYPE="REFERENCE">Parmar 1998</LINK>. We abstracted site of recurrence, where possible. For dichotomous outcomes (e.g. complete tumour response and adverse events), we extracted the number of patients in each treatment arm who experienced the outcome of interest and the number of patients assessed per endpoint, in order to estimate a risk ratio. We abstracted adverse events by grade of toxicity. The time points at which outcomes were collected and reported were noted.<BR/>
</P>
<P>In addition, the following data were collected from the manuscript: identifiers (authors, title of publication, journal name and citation), tumour characteristics (recurrent, primary, inoperable, metastasis and maximum tumour diameter), baseline characteristics of study population (age, WHO performance status at the time of randomisation, initial disease stage), treatment allocated and number of patients randomised. The results and discrepancies of the data extraction were discussed in different meetings (DDH, GVM, JB, LL). The quality of the hyperthermia treatment of the different studies was determined in a consensus meeting (CVZ, DDH, GVM, JB, LL).</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2009-10-28 13:00:50 +0000" MODIFIED_BY="Gail Quinn">
<P>The risk of bias was assessed using the tool described in the Cochrane Handbook for Systematic Reviews of interventions (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>) addressing the following six domains:</P>
<P>Sequence generation (1), allocation concealment (2), blinding (3), incomplete outcome data (4), selective reporting of outcomes(5) and other potential threats to validity (6).</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2009-11-10 14:00:32 +0000" MODIFIED_BY="Gail Quinn">
<P>A weighted estimate of the typical treatment effect across studies was computed for the study outcomes. The risk ratio (RR) was used as the effect measure. For time-to-event outcomes such as survival analysis, the HR was used as effect measure. For these analyses, p-values and total events were used and the randomization ratio was 1:1 (<LINK REF="REF-Tierney-2007" TYPE="REFERENCE">Tierney 2007</LINK>). <LINK REF="REF-Tierney-2004" TYPE="REFERENCE">Tierney 2004</LINK> was used to facilitate the estimation of HRs from published summary statistics or data extracted from Kaplan-Meier curves.</P>
</EFFECT_MEASURES>
<MISSING_DATA MODIFIED="2009-10-22 18:06:04 +0100" MODIFIED_BY="[Empty name]">
<P>We did not impute missing outcome data; if only imputed outcome data were reported, we planned to contact trial authors to request data on the outcomes only among participants who were assessed.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2009-03-27 14:58:28 +0000" MODIFIED_BY="Clare Jess">
<P>Chi-square heterogeneity tests were used to test for statistical heterogeneity among trials. Since we anticipated that the trial results were heterogeneous, all analysis were performed using a random-effects model.</P>
</HETEROGENEITY_ASSESSMENT>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2010-01-28 13:39:48 +0000" MODIFIED_BY="Gail Quinn">
<STUDY_DESCRIPTION MODIFIED="2010-01-28 13:19:44 +0000" MODIFIED_BY="Gail Quinn">
<P>See:Characteristics of <LINK TAG="INCLUDED_STUDIES_DESCR" TYPE="SECTION">Included studies</LINK>;Characteristics of <LINK TAG="EXCLUDED_STUDIES_DESCR" TYPE="SECTION">Excluded studies</LINK>.<BR/>
</P>
<SEARCH_RESULTS MODIFIED="2010-01-22 16:20:59 +0000" MODIFIED_BY="[Empty name]">
<P>The process of selecting the included studies for this review is summarized in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> . Of the 143 published abstracts that were selected by the performed search, we excluded 117 abstracts. The studies described in these abstracts did not evaluate the interventions of interest (n = 2) or did not contain data of cervical patient characteristics (n = 24). In addition, a total of 91 abstracts were excluded due to the study characteristics presented, i.e. no RCT (n = 52), a review (n = 26) or a phase 1-2 trial (n = 13). Of the remaining 26 abstracts the full journal papers were screened (if available). After screening, 6 studies appeared to be not randomised, 2 were editorial papers and 1 had an unclear design. The remaining 6 different trials (11 published papers: <LINK REF="REF-Franckena-2008" TYPE="REFERENCE">Franckena 2008</LINK>; <LINK REF="STD-Chen-1997" TYPE="STUDY">Chen 1997</LINK>; <LINK REF="STD-Datta-1987" TYPE="STUDY">Datta 1987</LINK>; Harima 2000; <LINK REF="STD-Harima-2001" TYPE="STUDY">Harima 2001</LINK>; Sharma 1989; <LINK REF="STD-Sharma-1991" TYPE="STUDY">Sharma 1991</LINK>; <LINK REF="STD-van-der-Zee-2000" TYPE="STUDY">van der Zee 2000</LINK>; van der Zee 2001; van der Zee 2002; <LINK REF="STD-Vasanthan-2005" TYPE="STUDY">Vasanthan 2005</LINK>) were of RCTs (Phase 2 or 3) reporting radiotherapy together with a hyperthermia treatment (RHT) in one arm and radiotherapy only in the other arm. Of notice, the study of Chen et al included 120 patients with 4 treatment arms of which 2 treatment arms contained concomitant chemotherapy (<LINK REF="STD-Chen-1997" TYPE="STUDY">Chen 1997</LINK>). Since this analysis aimed to investigate the additional effect of hyperthermia on standard radiotherapy, we decided not to include the patients treated with concomitant chemotherapy in the pooled data analysis. Four ongoing studies that were identified from abstracts of congresses, online databases for trial registration and contact with experts (see table Characteristics of included studies) are not included in the present analysis.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2010-01-28 13:19:44 +0000" MODIFIED_BY="Gail Quinn">
<P>In 1987 Datta et al reported their results obtained in 53 patients with squamous cell cervical carcinoma, FIGO stage IIIB (<LINK REF="STD-Datta-1987" TYPE="STUDY">Datta 1987</LINK>). 64 Patients were randomly assigned to standard treatment only or combined treatment with local hyperthermia. Eleven patients were either lost to follow-up or received incomplete treatment leaving 53 assessable patients (RT n = 26; RHT n = 27) ). No information concerning actually delivered therapy was provided by the authors. RHT yielded superior treatment results, i.e. 58% (15 out of 26) versus 74% (20 out of 27) CR, 46% (12 out of 26) versus 67% (18 out of 27) pelvic failure free survival and 27% (7 out of 26) versus 59% (16 out of 27) DFS at 2 years. The authors reported no increase of treatment related morbidity although detailed information was not provided.</P>
<P>In 1991 Sharma et al reported their results obtained in 50 patients with cervical carcinoma FIGO stage II-IIIB (<LINK REF="STD-Sharma-1991" TYPE="STUDY">Sharma 1991</LINK>). Fifty patients were randomly assigned to RT or RHT. Two patients in each group were lost to follow-up whereas another 4 patients were not assessable for local tumour control after a minimal follow-up period of 18 months leaving 42 patients (i.e. 22 RT and 20 RHT group). No information concerning actually delivered therapy was provided by the authors. Strictly local tumour control was evaluated, i.e. any pelvic side wall or distant recurrence was ignored. No details are provided on the duration of follow-up. RHT yielded superior treatment results , i.e. 50% (11 out of 22) versus 30% (6 out of 20) LR at 18 months for patients treated with RT and RHT, respectively. The authors reported no increase of treatment related morbidity although detailed information was not provided for late toxicity.</P>
<P>In 1997 Chen et al reported their results obtained in a study including 120 patients with cervical carcinoma, FIGO stage IIB -IIIB (<LINK REF="STD-Chen-1997" TYPE="STUDY">Chen 1997</LINK>). One hundred and twenty patients were randomly assigned to 1 of 4 treatment groups, no detailed information concerning the randomisation procedure was provided. Treatment consisted of RT, RHT, radiotherapy combined with chemotherapy (CRT) and radiotherapy combined with both hyperthermia and chemotherapy (TRIPLE). Vaginal applicators were used for the hyperthermia intervention but no further details were provided regarding the hyperthermia technique. No information concerning actually delivered therapy was provided by the authors. Treatment results were not significantly different , i.e. 46% (14 out of 30) versus 60% (18 out of 30) complete remission for the RT and RHT group. The authors reported no increase of acute treatment related rectal and bladder morbidity between the treatment groups although detailed information about the grade of toxicity was not provided. For the pooled data analysis we excluded those patients treated with concomitant chemotherapy (n=60).</P>
<P>In 2000 van der Zee et al reported their results obtained in a multicenter study including 114 patients with cervical carcinoma FIGO stage IIB-IVA (<LINK REF="STD-van-der-Zee-2000" TYPE="STUDY">van der Zee 2000</LINK>). Twenty-six patients did not complete radiotherapy treatment as planned because of insufficient tumour regression (n = 8 and n = 3), exceeding normal tissue dose constraints (n = 1 and n = 2), development of metastatic disease (n = 3 and n = 0), inability to access the cervical canal (n = 1 and n = 2), a cervical stump tumour (n = 0 and n = 2), intercurrent death (n = 1 and n = 1) and unknown (n = 3) in the control and experimental group, respectively. Median follow up was 43 months. RHT yielded superior treatment results i.e. 57% (32 out of 56) versus 83% (48 out of 58) CR, 41% versus 61% pelvic failure free survival and 27% versus 51% OS at 3 years for patients treated with RT and RHT, respectively. No difference in acute and late grade 3 to 4 treatment related rectal and/or bladder morbidity was observed.</P>
<P>In 2001 Harima et al reported their results obtained in a study including 40 patients with cervical carcinoma FIGO stage IIIB (<LINK REF="STD-Harima-2001" TYPE="STUDY">Harima 2001</LINK>). Mean follow-up was 25 (3.5 to 60.1) and 36 (5.9 to 64.3) months for the RT and RHT group, respectively. RHT yielded superior treatment results, i.e. 50% (10 out of 20) versus 80% (16 out of 20) CR; 50% versus 20% pelvic failure rate; 45% versus 64% DFS and 48% versus 58% OS at 3 years for patients treated with RT and RHT, respectively. Toxicity was not significantly different between treatment groups. However, in contrast to the RT group where no acute or late toxicity of any grade was observed, in the RHT group 1 patient had grade 3 acute bowel toxicity (RTOG score, <LINK REF="REF-Rubin-1995" TYPE="REFERENCE">Rubin 1995</LINK>) and 2 patients developed grade 3 late bowel toxicity (obstructive colonic ileus and sigmoid-ileum fistula) after 1.5 and 2 years after treatment.</P>
<P>In 2005 Vasanthan et al reported their results obtained in a multicenter study in 110 patients with cervical carcinoma FIGO stage IIB -IVA (<LINK REF="STD-Vasanthan-2005" TYPE="STUDY">Vasanthan 2005</LINK>). Median follow-up was 15.7 months for all patients and 17.2 months for surviving patients. Treatment results did not differ between RT and RHT groups. A subgroup analysis in 56 patients with stage IIB cervical carcinoma yielded a significantly worse survival for the RHT group whereas local control was similar for the 2 treatment groups. No details are provided concerning the cause of death or the location of disease recurrence. No significant difference in acute or late toxicity was observed. Grade 3 acute toxicity was observed only in 1 patient treated with RHT (grade 3 blister). Grade 3 bowel toxicity was equally distributed between treatment groups (n = 2 per group). One grade 4 bowel toxicity was observed in a patient treated with RT.<BR/>
</P>
<SUBSECTION>
<HEADING LEVEL="4">Quality of treatment</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Radiotherapy</HEADING>
<P>In general, state of the art treatment of LACC requires adequate EBRT combined with brachytherapy. Thus, EBRT doses between 45 to 50 Gy and cumulative doses between 70 to 90 Gy to 'Point A' are considered standard. Reported radiation doses delivered do not provide any information concerning the adequacy of tumour dose delivery. Except for the Datta study (<LINK REF="STD-Datta-1987" TYPE="STUDY">Datta 1987</LINK>), all standard radiotherapy protocols included combined treatment with EBRT and brachytherapy. To study the beneficial effect of any additional intervention to standard treatment ideally requires strictly standardized treatment protocols. Not surprisingly, taken the life span and geographical distribution of the 6 studies published, standard treatment varies significantly. Moreover, except for one study (<LINK REF="STD-Harima-2001" TYPE="STUDY">Harima 2001</LINK>) EBRT was not standardized within each study. Strictly adhering to the predefined quality criteria would mean that only three studies using hyperthermia treatment would qualify as adequate for review analysis. However, standard radiotherapy in these studies varied as well and would result in cancellation of the review. Taking this into account we decided to accept the variation in radiation therapy and hyperthermia techniques as well as the lack of description of the quality criteria in the manuscripts leaving 'randomised clinical study, including at least 20 patients' as major selection criterion. In doing so, we do realize that any outcome based on this analysis can only be suggestive and not conclusive.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Hyperthermia</HEADING>
<P>The quality of the hyperthermia treatments is difficult to assess from the published information. Dose-effect relationships have been established for several hyperthermia dose parameters derived from the measured temperatures and the duration of heating, and taking into account the temperature distribution. In clinical practice, however, the number of thermometry sites is limited and in cervical cancer the thermometry probes are usually placed near the centre of the tumour. The temperature data are therefore not informative on what the hyperthermia dose has been in the entire tumour volume (<LINK REF="REF-van-der-Zee-2008" TYPE="REFERENCE">van der Zee 2008</LINK>). Other studies indicate that the applied energy distribution in the tumour volume can be used as a quality indicator (<LINK REF="REF-van-der-Zee-2008" TYPE="REFERENCE">van der Zee 2008</LINK>). The energy distribution can be estimated from the information provided in the publications. In five studies, electromagnetic (EM) radiation was used for heating. Chen et al used an intravaginal applicator with an unspecified source of energy, which may have been electromagnetic radiation as well. EM radiation was applied radiatively or capacitively (<LINK REF="STD-Chen-1997" TYPE="STUDY">Chen 1997</LINK>). Van der Zee et al used three different radiative EM systems with similar energy depositions in pelvis-sized phantoms (<LINK REF="STD-van-der-Zee-2000" TYPE="STUDY">van der Zee 2000</LINK>).</P>
<P>With EM radiation at a frequency of 70 to 120 MHz, energy input from around the pelvis and the use of interference, the energy is deposited widely in the pelvic region (<LINK REF="REF-Gellermann-2005" TYPE="REFERENCE">Gellermann 2005</LINK>; <LINK REF="REF-Sreenivasa-2003" TYPE="REFERENCE">Sreenivasa 2003</LINK>). In the other studies, capacitive heating systems were used. With capacitive heating (8 to 27 MHz) between two large electrodes placed opposite on the patient's skin it is also possible to get energy deposition widely in the pelvic region, provided there is an appropriate patient selection and treatment procedure (<LINK REF="REF-van-der-Zee-2005" TYPE="REFERENCE">van der Zee 2005</LINK>). Subcutaneous fat tissue is preferentially heated by capacitive heating and must be cooled to allow for sufficient energy input into deeper seated tissues. Superficial skin cooling can limit the temperature increase in subcutaneous fat to an acceptable level to a depth of approximately 2 cm (<LINK REF="REF-Rhee-1991" TYPE="REFERENCE">Rhee 1991</LINK>). With thicker subcutaneous fat layers, the high temperature in the deeper subcutaneous fat will limit the total power input. Further more, when a smaller (intravaginal) electrode is used in combination with one or two large external electrode(s) there will be a steep gradient of energy deposition with the maximum around the small electrode. The energy level normalized to maximum will fall below 25% within 1 to 2 cm from the intravaginal electrode (<LINK REF="REF-Hiraki-2000" TYPE="REFERENCE">Hiraki 2000</LINK>). With capacitive heating using an intravaginal electrode, only the central part of the tumour can be expected to be heated to therapeutic temperatures.</P>
<P>
<LINK REF="STD-Datta-1987" TYPE="STUDY">Datta 1987</LINK>
<BR/>Hyperthermia was given twice weekly before radiotherapy. The total number of treatments was not reported, it could have been 12 during 6 weeks of EBRT. The duration per treatment was 15 to 20 minutes after reaching a temperature of approximately 42.5°C, measured in the cervical canal. Hyperthermia was induced by a 27 MHz capacitive system with two external electrodes. The authors do not report subcutaneous fat thickness as an eligibility criterion, nor skin cooling, nor the applied power.</P>
<P>
<LINK REF="STD-Sharma-1991" TYPE="STUDY">Sharma 1991</LINK>
<BR/>Hyperthermia was given 3 times per week for a total of 12 treatments of 45 minutes duration, before radiotherapy. A 27 MHz capacitive heating system was used with a large external and an intravaginal electrode. Temperatures were measured by a thermocouple attached to the intravaginal electrode. In most patients, the intravaginal temperature was 43°C for 30 minutes.</P>
<P>
<LINK REF="STD-Chen-1997" TYPE="STUDY">Chen 1997</LINK>
<BR/>Hyperthermia was given twice weekly after radiotherapy for a total of 6 treatments of 45 minutes at a temperature of 42° with an intravaginal technique. Further details of treatment are not reported.</P>
<P>
<LINK REF="STD-van-der-Zee-2000" TYPE="STUDY">van der Zee 2000</LINK>
<BR/>Hyperthermia was applied by three centres which all used a radiative hyperthermia system. Hyperthermia was given once a week after radiotherapy, for a total of 5 treatments of 60 minutes after reaching 42°C, or maximum 90 minutes. The mean power input and achieved intraluminal (rectal, bladder and vaginal) temperatures were reported by the centre recruiting the most patients and were reported separately: average 706 Watts and 40.6°C (<LINK REF="REF-Fatehi-2007" TYPE="REFERENCE">Fatehi 2007</LINK>).</P>
<P>
<LINK REF="STD-Harima-2001" TYPE="STUDY">Harima 2001</LINK>
<BR/>Hyperthermia was given once a week after RT, for a total 3 treatments of 60 minutes duration. Hyperthermia was induced with the Thermotron 8 MHz capacitive system with two external electrodes. Patients with subcutaneous fat layer of less than 4 cm were eligible.The authors do not report to have used pre-cooling. The applied power was 800 to1500 W. Intratumour temperature measurements were done with 4-point thermocouple probes; an average temperature of 40.6°C was achieved.</P>
<P>
<LINK REF="STD-Vasanthan-2005" TYPE="STUDY">Vasanthan 2005</LINK>
<BR/>Five centres participated in this study. Hyperthermia was given once weekly before or after radiotherapy, for a total of 5 treatments of 60 minutes duration.</P>
<P>The description of applied heating techniques is incomplete. All centres used a 8 MHz capacitive heating system with, probably in the majority of patients, an intravaginal electrode (<LINK REF="REF-van-der-Zee-2005" TYPE="REFERENCE">van der Zee 2005</LINK>). A subcutaneous fat thickness of up to 3 cm was accepted; pre-cooling of skin was reported by only one centre. The level of power input was reported by only one centre: a mean of 520 W, which is relatively low. Centrally measured average temperatures ranged between 38.1 and 42°C.</P>
<P>The hyperthermia techniques using radiative electromagnetic heating or capacitive heating with external electrodes only can be considered adequate (<LINK REF="STD-Datta-1987" TYPE="STUDY">Datta 1987</LINK>; <LINK REF="STD-Harima-2001" TYPE="STUDY">Harima 2001</LINK>; <LINK REF="STD-van-der-Zee-2000" TYPE="STUDY">van der Zee 2000</LINK>). In the study of Sharma et al the effect on the central tumour was the main endpoint, for which the used intravaginal heating can be considered adequate (<LINK REF="STD-Sharma-1991" TYPE="STUDY">Sharma 1991</LINK>). In the studies by Chen et al and Vasanthan et al the applied intravaginal heating (in the majority of patients) must be considered inadequate for treatment of the advanced tumours included in their studies (<LINK REF="STD-Chen-1997" TYPE="STUDY">Chen 1997</LINK>; <LINK REF="STD-Vasanthan-2005" TYPE="STUDY">Vasanthan 2005</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2009-10-22 18:06:04 +0100" MODIFIED_BY="[Empty name]">
<P>From the retrieved studies, eight studies were excluded for this review mainly because of the used study design (<LINK REF="STD-El-Sharouni-1997" TYPE="STUDY">El Sharouni 1997</LINK>; <LINK REF="STD-Fujiwara-1987" TYPE="STUDY">Fujiwara 1987</LINK>; <LINK REF="STD-Gupta-1999" TYPE="STUDY">Gupta 1999</LINK>; <LINK REF="STD-Hasegawa-1989" TYPE="STUDY">Hasegawa 1989</LINK>; <LINK REF="STD-Hornback-1986" TYPE="STUDY">Hornback 1986</LINK>; <LINK REF="STD-Kohno-1990" TYPE="STUDY">Kohno 1990</LINK>). One study was not assessable due to limited data (<LINK REF="STD-Li-1993" TYPE="STUDY">Li 1993</LINK>) and one study could not be included because the trial is still ongoing (<LINK REF="STD-Prosnitz-2002" TYPE="STUDY">Prosnitz 2002</LINK>). </P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2010-01-28 13:19:44 +0000" MODIFIED_BY="Gail Quinn">
<P>The methodological quality of the included studies is shown in the table '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' and is summarized in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>.</P>
<P>All six included studies reported on a randomisation process. In one study (<LINK REF="STD-Chen-1997" TYPE="STUDY">Chen 1997</LINK>) allocation concealment might be questionable. Although there was no blinding in any study, this is unlikely to affect outcome. All six studies were wihtout missing outcome data . No other problems were detected in any of the six studies that might have introduced a serious risk of bias. However, several other issues have to be considered. Of importance, uniformity in treatment was far from optimal, both for hyperthermia and radiotherapy. For example in hyperthermia the sequencing of radiotherapy and hyperthermia and the interval between radiotherapy and hyperthermia differed between and within (<LINK REF="STD-Vasanthan-2005" TYPE="STUDY">Vasanthan 2005</LINK>) the studies. Similarly the radiation technique, the total radiation dose applied and overall treatment time differed between and within the studies (<LINK REF="STD-van-der-Zee-2000" TYPE="STUDY">van der Zee 2000</LINK>; <LINK REF="STD-Vasanthan-2005" TYPE="STUDY">Vasanthan 2005</LINK>). For the different outcome measures only three or four out of six studies can be used for pooled data analysis due to the lack of reported p-values. Finally, overall the number of patients included in these six studies is small whereas the majority (i.e. 74%) had FIGO stage IIIB LACC.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2010-01-28 13:39:48 +0000" MODIFIED_BY="Gail Quinn">
<SUBSECTION>
<HEADING LEVEL="3">Complete response</HEADING>
<P>Using complete tumour response at the end of treatment as endpoint in the pooled data analysis including 267 study patients (<LINK REF="STD-Datta-1987" TYPE="STUDY">Datta 1987</LINK>; <LINK REF="STD-Chen-1997" TYPE="STUDY">Chen 1997</LINK>; <LINK REF="STD-van-der-Zee-2000" TYPE="STUDY">van der Zee 2000</LINK>; <LINK REF="STD-Harima-2001" TYPE="STUDY">Harima 2001</LINK>) yields a significantly better treatment outcome following RHT (RR 0.56 (95% CI 0.39 to 0.79); p &lt; 0.001; <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Local recurrence</HEADING>
<P>Using local recurrence as endpoint in the pooled data analysis including 264 study patients (<LINK REF="STD-van-der-Zee-2000" TYPE="STUDY">van der Zee 2000</LINK>; <LINK REF="STD-Harima-2001" TYPE="STUDY">Harima 2001</LINK>; <LINK REF="STD-Vasanthan-2005" TYPE="STUDY">Vasanthan 2005</LINK>) yields a significantly reduced local recurrence rate (HR 0.48 (95% CI 0.37 to 0.63); p &lt; 0.001; <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Overall survival</HEADING>
<P>Using overall survival as endpoint in the pooled data analysis including 264 study patients (<LINK REF="STD-van-der-Zee-2000" TYPE="STUDY">van der Zee 2000</LINK>; <LINK REF="STD-Harima-2001" TYPE="STUDY">Harima 2001</LINK>; <LINK REF="STD-Vasanthan-2005" TYPE="STUDY">Vasanthan 2005</LINK>) yielded a significantly better survival for the combined treatment group (RHT) (HR 0.67; 95% CI 0.45 to 0.99; p = 0.05; <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>; <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Toxicity</HEADING>
<P>Using acute toxicity as endpoint in the pooled data analysis including 310 study patients (<LINK REF="STD-Sharma-1991" TYPE="STUDY">Sharma 1991</LINK>; <LINK REF="STD-van-der-Zee-2000" TYPE="STUDY">van der Zee 2000</LINK>; <LINK REF="STD-Harima-2001" TYPE="STUDY">Harima 2001</LINK>; <LINK REF="STD-Vasanthan-2005" TYPE="STUDY">Vasanthan 2005</LINK>) yielded no difference in acute treatment related toxicity between both treatment groups (RR 0.99 (95% CI 0.30 to 3.31); p = 0.99; <LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>; <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>). Similarly, the pooled data analysis using late toxicity as endpoint including 264 study patients (<LINK REF="STD-van-der-Zee-2000" TYPE="STUDY">van der Zee 2000</LINK>; <LINK REF="STD-Harima-2001" TYPE="STUDY">Harima 2001</LINK>; <LINK REF="STD-Vasanthan-2005" TYPE="STUDY">Vasanthan 2005</LINK>) yielded no difference in late toxicity between both treatment groups (RR 1.01 (CI 95% 0.44 to 2.30); p = 0.98.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2010-02-01 14:02:50 +0000" MODIFIED_BY="Gail Quinn">
<P>The results of the present analysis with respect to the endpoints studied, i.e. complete response rate following treatment, local recurrence, OS and treatment related toxicity grade 3 to 4 indicates a significant improvement of local (pelvic) tumour control and overall survival for the combined treatment modality (RHT) whereas acute and late toxicity was not significantly different between both treatment groups. In four of six studies (<LINK REF="STD-Datta-1987" TYPE="STUDY">Datta 1987</LINK>; <LINK REF="STD-Harima-2001" TYPE="STUDY">Harima 2001</LINK>; <LINK REF="STD-Sharma-1991" TYPE="STUDY">Sharma 1991</LINK>; <LINK REF="STD-van-der-Zee-2000" TYPE="STUDY">van der Zee 2000</LINK>) a significantly improved treatment outcome was observed by adding hyperthermia to standard radiotherapy, whereas in two studies no significant difference between both treatments was observed (<LINK REF="STD-Chen-1997" TYPE="STUDY">Chen 1997</LINK>; <LINK REF="STD-Vasanthan-2005" TYPE="STUDY">Vasanthan 2005</LINK>).</P>
<P>In contrast, in one study (<LINK REF="STD-Vasanthan-2005" TYPE="STUDY">Vasanthan 2005</LINK>) an inferior survival was observed in a subgroup of patients with FIGO stage IIB treated with RHT, although no further information is provided on the cause of death, whereas local tumour control was similar for both treatment groups. Sharma et al report on an increased rate of distant metastases in the RHTgroup although the difference is not significant and no survival data are provided (<LINK REF="STD-Sharma-1991" TYPE="STUDY">Sharma 1991</LINK>). Of interest, the patient population differed significantly between these studies as the percentage of patients with FIGO stage IIIB disease varied between 38 to 77 % (<LINK REF="STD-Chen-1997" TYPE="STUDY">Chen 1997</LINK>; <LINK REF="STD-Vasanthan-2005" TYPE="STUDY">Vasanthan 2005</LINK>) and between 70 to 100% (<LINK REF="STD-Datta-1987" TYPE="STUDY">Datta 1987</LINK>; <LINK REF="STD-Harima-2001" TYPE="STUDY">Harima 2001</LINK>; <LINK REF="STD-Sharma-1991" TYPE="STUDY">Sharma 1991</LINK>; <LINK REF="STD-van-der-Zee-2000" TYPE="STUDY">van der Zee 2000</LINK>) in the two studies showing no difference and the four studies showing a beneficial effect of hyperthermia.</P>
<P>Regarding treatment related toxicity, all studies reported treatment related toxicity. Three studies (<LINK REF="STD-Datta-1987" TYPE="STUDY">Datta 1987</LINK>; <LINK REF="STD-Sharma-1991" TYPE="STUDY">Sharma 1991</LINK>; <LINK REF="STD-Chen-1997" TYPE="STUDY">Chen 1997</LINK>) found no effect on normal tissue toxicity, although no further details were provided. Two trials (<LINK REF="STD-van-der-Zee-2000" TYPE="STUDY">van der Zee 2000</LINK>;<LINK REF="STD-Vasanthan-2005" TYPE="STUDY">Vasanthan 2005</LINK>) reported no increaseof acute or late toxicity. One trial (<LINK REF="STD-Harima-2001" TYPE="STUDY">Harima 2001</LINK>) observed an increased late bowel toxicity in 2 out of 20 patients treated with RHT as compared to 0 out of 20 patients treated with RT.<BR/>
</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2009-10-28 13:26:32 +0000" MODIFIED_BY="Gail Quinn">
<IMPLICATIONS_PRACTICE MODIFIED="2009-10-28 13:26:32 +0000" MODIFIED_BY="Gail Quinn">
<P>Taken the limited number of patients available for this analysis, the over-representation of FIGO stage IIIB disease and the methodological flaws as discussed, it is not possible to draw definite conclusions regarding the beneficial effect of hyperthermia added to standard radiotherapy. Treatment related severe toxicity, i.e. grade 3 to 4 seems not to be affected by the addition of hyperthermia to standard radiotherapy treatment. However, the available data do suggest that superior local tumour control rates and overall survival can be achieved in patients with LACC by adding hyperthermia to standard radiotherapy. Although the available data mainly apply for patients presenting with FIGO stage IIIB disease, radiobiological considerations suggest a possible benefit for its use in other locally advanced stages as well. Based on the results of several recent RCTs investigating the role of adding chemotherapy to radiotherapy this treatment combination is currently considered standard in LACC. Considering the results of this analysis and the finding that the effect of adding chemotherapy to radiotherapy on survival seems to decrease with increasing tumour stage hyperthermia should be considered as an alternative in case chemotherapy is contra-indicated, especially in higher tumour stages.<BR/>
</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2009-10-05 15:38:33 +0100" MODIFIED_BY="[Empty name]">
<P>Taken the therapeutic benefit obtained, that is almost doubling of a durable local control with an associated increase in overall survival, without affecting treatment associated toxicity and the relatively low costs per patient, a limited number of clinical restrictions for its application, further investigation of the role of hyperthermia in a large scaled randomised trial is warranted. In case of a substantiated therapeutic gain this treatment modality should become available to all patients with this life threatening but potentially curable disease.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2009-10-23 14:00:44 +0100" MODIFIED_BY="[Empty name]">
<P>We would like to thank Ruud Houben for his contribution on statistics.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>none</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2009-04-20 18:55:23 +0100" MODIFIED_BY="[Empty name]">
<P>L Lutgens provided background information, methodology support and co drafted the review. M Pijls-Johannesma designed the literature search strategy, developed methodology and co-drafted review. J van der Zee provided expertise on hyperthermia and co-drafted the review. G van Mastrigt, D de Haas, J.Buijsen, G.Lammering, D De Ruysscher, and P Lambin co-drafted review.<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2010-01-28 13:19:44 +0000" MODIFIED_BY="Gail Quinn">
<P>There were several discrepancies between the methods published in the protocol and those used in the actual review.</P>
<P>Firstly, as a consequence of limited data, sensitivity analyses and subgroup analyses could not be performed.</P>
<P>A second discrepancy was the presentation of the outcomes for overall survival, disease free survival and local regional tumour control. According to the protocol this should have been in terms of 2-year and 5-year ratios.However, we decided to report the HR instead extracted from the Kaplan Meier curves (Tierney 2004;Tierney 2007). . Moreover, due to limited reporting on disease free survival we were not able to perform analyses for this outcome.</P>
<P>Finally, in order to determine the risk of bias we planned to assess the quality of the included studies by the following criteria:</P>
<UL>
<LI>Was the randomisation process adequate?</LI>
<LI>Was there adequate allocation concealment?</LI>
<LI>Was the analysis performed according to intention to treat?</LI>
<LI>Were the groups similar at baseline for the most important prognostic indicators?</LI>
<LI>Were eligibility criteria specified?</LI>
<LI>Were losses to follow up fully accounted for?</LI>
<LI>Was the withdrawal/drop-out rate unlikely to cause bias?</LI>
<LI>Were co-interventions which may have influenced the results controlled for?</LI>
</UL>
<P>However, in the present review the risk of bias was assessed using the tool described in the Cochrane Handbook for Systematic Reviews of interventions (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>) addressing the following 6 domains: Sequence generation (1), allocation concealment (2), blinding (3), incomplete outcome data (4), selective reporting of outcomes (5) and other potential threats to validity (6).</P>
<P>See <LINK REF="FIG-08" TYPE="FIGURE">Figure 8</LINK> for list of abbreviations used throughout this review.<BR/>
<BR/>
</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2010-02-08 12:03:34 +0000" MODIFIED_BY="Gail Quinn">
<STUDIES MODIFIED="2009-11-10 13:53:36 +0000" MODIFIED_BY="Gail Quinn">
<INCLUDED_STUDIES MODIFIED="2009-11-10 13:51:09 +0000" MODIFIED_BY="Gail Quinn">
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-1997" MODIFIED="2009-10-28 14:32:39 +0000" MODIFIED_BY="Gail Quinn" NAME="Chen 1997" YEAR="1997">
<REFERENCE MODIFIED="2009-10-28 14:32:39 +0000" MODIFIED_BY="Gail Quinn" NOTES="&lt;p&gt;H. W. Chen, Department of Oncology, First Clinical College, Xi'an Medical University, Xi'an&lt;/p&gt;" NOTES_MODIFIED="2009-10-28 14:32:39 +0000" NOTES_MODIFIED_BY="Gail Quinn" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Chen HW, Fan JJ, Luo W</AU>
<TI>A randomized trial of hyperthermo-radiochemotherapy for uterine cervix cancer</TI>
<SO>Chinese Journal of Clinical Oncology</SO>
<YR>1997</YR>
<VL>24</VL>
<NO>4</NO>
<PG>249-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Datta-1987" MODIFIED="2009-10-23 10:54:19 +0100" MODIFIED_BY="[Empty name]" NAME="Datta 1987" YEAR="1987">
<REFERENCE MODIFIED="2009-10-23 10:54:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>NR Datta, AK Bose, HK Kapoor</AU>
<TI>Thermoradiotherapy in the management of Carcinoma Cervix (Stage IIIB): A controlled Clinical Study</TI>
<SO>Indian Medical Gazette</SO>
<YR>1987</YR>
<VL>121</VL>
<PG>68-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harima-2001" MODIFIED="2009-04-10 14:08:34 +0100" MODIFIED_BY="[Empty name]" NAME="Harima 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-04-10 14:08:34 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Department of Radiology, Kansai Medical University, Moriguchi, Osaka, Japan. harima@takii.kmu.ac.jp&lt;/p&gt;" NOTES_MODIFIED="2009-04-10 14:08:34 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Harima Y, Nagata K, Harima K, Ostapenko VV, Tanaka Y, Sawada S</AU>
<TI>A randomized clinical trial of radiation therapy versus thermoradiotherapy in stage IIIB cervical carcinoma</TI>
<SO>International Journal of Hyperthermia the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group</SO>
<YR>2001</YR>
<VL>17</VL>
<NO>2</NO>
<PG>97-105</PG>
<IDENTIFIERS MODIFIED="2009-04-10 14:08:34 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-04-10 14:08:34 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="Index-Medicus"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sharma-1991" MODIFIED="2009-11-10 13:50:48 +0000" MODIFIED_BY="Gail Quinn" NAME="Sharma 1991" YEAR="1991">
<REFERENCE MODIFIED="2009-11-10 13:50:48 +0000" MODIFIED_BY="Gail Quinn" NOTES="&lt;p&gt;Department of Radiation Therapy, Post Graduate Institute of Medical Education and Research, Chandigarh, India.&lt;/p&gt;" NOTES_MODIFIED="2009-11-10 13:50:48 +0000" NOTES_MODIFIED_BY="Gail Quinn" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sharma S, Singhal S, Sandhu AP, Ghoshal S, Gupta BD, Yadav NS</AU>
<TI>Local thermo-radiotherapy in carcinoma cervix: improved local control versus increased incidence of distant metastasis</TI>
<SO>Asia Oceania Journal of Obstetrics and Gynaecology AOFOG</SO>
<YR>1991</YR>
<VL>17</VL>
<NO>1</NO>
<PG>5-12</PG>
<IDENTIFIERS MODIFIED="2009-11-10 13:50:48 +0000" MODIFIED_BY="Gail Quinn"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-der-Zee-2000" MODIFIED="2009-11-10 13:50:55 +0000" MODIFIED_BY="Gail Quinn" NAME="van der Zee 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-11-10 13:50:55 +0000" MODIFIED_BY="Gail Quinn" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Van der Zee J, Gonzalez-Gonzales D, Van RGC, Van DJDP, Van PWLJ, Hart AAM</AU>
<TI>Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: A prospective, randomised, multicentre trial</TI>
<SO>Lancet</SO>
<YR>2000</YR>
<VL>355</VL>
<NO>9210</NO>
<PG>1119-25</PG>
<IDENTIFIERS MODIFIED="2009-11-10 13:50:55 +0000" MODIFIED_BY="Gail Quinn"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vasanthan-2005" MODIFIED="2009-11-10 13:51:09 +0000" MODIFIED_BY="Gail Quinn" NAME="Vasanthan 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-11-10 13:51:09 +0000" MODIFIED_BY="Gail Quinn" NOTES="&lt;p&gt;Department of Radiation Oncology, Cancer Institute, Chennai, India.&lt;/p&gt;" NOTES_MODIFIED="2009-11-10 13:51:09 +0000" NOTES_MODIFIED_BY="Gail Quinn" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Vasanthan A, Mitsumori M, Park JH, Zhi Fan Z, Yu Bin Z, Oliynychenko P et al</AU>
<TI>Regional hyperthermia combined with radiotherapy for uterine cervical cancers: A multi-institutional prospective randomized trial of the international atomic energy agency</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>2005</YR>
<VL>61</VL>
<NO>1</NO>
<PG>145-53</PG>
<IDENTIFIERS MODIFIED="2009-11-10 13:51:09 +0000" MODIFIED_BY="Gail Quinn"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2009-11-10 13:53:36 +0000" MODIFIED_BY="Gail Quinn">
<STUDY DATA_SOURCE="PUB" ID="STD-El-Sharouni-1997" MODIFIED="2009-11-10 13:51:27 +0000" MODIFIED_BY="Gail Quinn" NAME="El Sharouni 1997" YEAR="1997">
<REFERENCE MODIFIED="2009-11-10 13:51:27 +0000" MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>El Sharouni SY, Warlam Rodenhuis CC, De LAAC, Bouma P, Heintz APM</AU>
<TI>Radiotherapy in combination with regional hyperthermia in treating cervical cancer patients</TI>
<SO>International Journal of Gynecological Cancer</SO>
<YR>1997</YR>
<VL>7</VL>
<NO>Suppl 2</NO>
<PG>38</PG>
<IDENTIFIERS MODIFIED="2009-11-10 13:51:27 +0000" MODIFIED_BY="Gail Quinn"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fujiwara-1987" MODIFIED="2009-10-28 14:35:46 +0000" MODIFIED_BY="Gail Quinn" NAME="Fujiwara 1987" YEAR="1987">
<REFERENCE MODIFIED="2009-10-28 14:35:46 +0000" MODIFIED_BY="Gail Quinn" NOTES="&lt;p&gt;English&lt;/p&gt;" NOTES_MODIFIED="2009-10-28 14:35:46 +0000" NOTES_MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fujiwara K, Kohno I, Sekiba K</AU>
<TI>Therapeutic effect of hyperthermia combined with chemotherapy on vulvar and vaginal carcinoma</TI>
<SO>Acta Medica Okayama</SO>
<YR>1987</YR>
<VL>41</VL>
<NO>2</NO>
<PG>55-62</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="Index-Medicus"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gupta-1999" MODIFIED="2009-10-28 14:36:18 +0000" MODIFIED_BY="Gail Quinn" NAME="Gupta 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-10-28 14:36:18 +0000" MODIFIED_BY="Gail Quinn" NOTES="&lt;p&gt;Department of Radiation Oncology, William Beaumont Hospital, Royal Oak, MI 48073, USA.&lt;/p&gt;" NOTES_MODIFIED="2009-10-28 14:36:18 +0000" NOTES_MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gupta AK, Vicini FA, Frazier AJ, Barth Jones DC, Edmundson GK, Mele E et al</AU>
<TI>Iridium-192 transperineal interstitial brachytherapy for locally advanced or recurrent gynecological malignancies</TI>
<SO>International Journal of Radiation Oncology, Biology and Physics</SO>
<YR>1999</YR>
<VL>43</VL>
<NO>5</NO>
<PG>1055-60</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="Index-Medicus"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hasegawa-1989" MODIFIED="2009-11-10 13:53:36 +0000" MODIFIED_BY="Gail Quinn" NAME="Hasegawa 1989" YEAR="1989">
<REFERENCE MODIFIED="2009-11-10 13:53:36 +0000" MODIFIED_BY="Gail Quinn" NOTES="&lt;p&gt;Cytological and histological effects of regional hyperthermia and radiation in cancer of the uterine cervix&lt;/p&gt;" NOTES_MODIFIED="2009-11-10 13:53:36 +0000" NOTES_MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hasegawa K, Kinugasa M, Nishino R, Kimura A, Yukimura N, Ohtsu F et al</AU>
<TI>Cytological and histological effects of regional hyperthermia and radiation in cancer of the uterine cervix</TI>
<SO>Journal of Japan Society for Cancer Therapy</SO>
<YR>1989</YR>
<VL>24</VL>
<NO>8</NO>
<PG>1526-38</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="Index-Medicus"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hornback-1986" MODIFIED="2009-10-28 14:36:37 +0000" MODIFIED_BY="Gail Quinn" NAME="Hornback 1986" YEAR="1986">
<REFERENCE MODIFIED="2009-10-28 14:36:37 +0000" MODIFIED_BY="Gail Quinn" NOTES="&lt;p&gt;English&lt;/p&gt;" NOTES_MODIFIED="2009-10-28 14:36:37 +0000" NOTES_MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hornback NB, Shupe RE, Shidnia H, Marshall CU, Lauer T</AU>
<TI>Advanced stage IIIB cancer of the cervix treatment by hyperthermia and radiation</TI>
<SO>Gynecologic Oncology</SO>
<YR>1986</YR>
<VL>23</VL>
<NO>2</NO>
<PG>160-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="Index-Medicus"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kohno-1990" NAME="Kohno 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kohno I, Kobashi Y, Hasegawa T, Fujiwra K, Hayase R, Sekiba K</AU>
<TI>Combines effect of hyperthermia with radiation for uterine cervical cancer</TI>
<SO>Strahlentherapie und Onkologie</SO>
<YR>1990</YR>
<VL>166</VL>
<NO>5</NO>
<PG>348</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="Cn-00427136"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-1993" MODIFIED="2009-10-28 14:36:54 +0000" MODIFIED_BY="Gail Quinn" NAME="Li 1993" YEAR="1993">
<REFERENCE MODIFIED="2009-10-28 14:36:54 +0000" MODIFIED_BY="Gail Quinn" NOTES="&lt;p&gt;Tianjin Cancer Hospital,Tianjin&lt;/p&gt;" NOTES_MODIFIED="2009-10-28 14:36:54 +0000" NOTES_MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li RY</AU>
<TI>Intracavitary microwave hyperthermia combined with external irradiation in the treatment of cervical carcinoma</TI>
<SO>Chinese Journal of Clinical Oncology</SO>
<YR>1993</YR>
<VL>20</VL>
<NO>1</NO>
<PG>32-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prosnitz-2002" MODIFIED="2009-10-28 14:37:04 +0000" MODIFIED_BY="Gail Quinn" NAME="Prosnitz 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-10-28 14:37:04 +0000" MODIFIED_BY="Gail Quinn" NOTES="&lt;p&gt;L. Prosnitz, Department of Radiation Oncology, Duke University, Medical Center, Durham, NC 27710&lt;/p&gt;" NOTES_MODIFIED="2009-10-28 14:37:04 +0000" NOTES_MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prosnitz L</AU>
<TI>A new phase III trial for treatment of carcinoma of the cervix</TI>
<SO>International Journal of Hyperthermia</SO>
<YR>2002</YR>
<VL>18</VL>
<NO>1</NO>
<PG>31-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2009-10-22 12:03:49 +0100" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES MODIFIED="2009-10-28 14:38:07 +0000" MODIFIED_BY="Gail Quinn">
<STUDY DATA_SOURCE="PUB" ID="STD-Harima" NAME="Harima" YEAR="">
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Piotrkowicz" MODIFIED="2009-10-22 08:16:46 +0100" MODIFIED_BY="[Empty name]" NAME="Piotrkowicz" YEAR="">
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prosnitz" NAME="Prosnitz" YEAR="">
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-RADCHOC" MODIFIED="2009-10-28 14:38:07 +0000" MODIFIED_BY="Gail Quinn" NAME="RADCHOC" YEAR="">
<IDENTIFIERS MODIFIED="2009-03-06 13:49:44 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2010-02-08 12:03:34 +0000" MODIFIED_BY="Gail Quinn">
<ADDITIONAL_REFERENCES MODIFIED="2010-02-08 12:03:34 +0000" MODIFIED_BY="Gail Quinn">
<REFERENCE ID="REF-Brady-1976" MODIFIED="2009-10-28 14:37:57 +0000" MODIFIED_BY="Gail Quinn" NAME="Brady 1976" TYPE="JOURNAL_ARTICLE">
<AU>Brady LW</AU>
<TI>Future prospects of radiotherapy in gynecologic oncology</TI>
<SO>Cancer</SO>
<YR>1976</YR>
<VL>38</VL>
<NO>Suppl 1</NO>
<PG>553-65</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="Abridged-Index-Medicus; Index-Medicus"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-De-Jaeger-1998" MODIFIED="2009-11-10 13:54:12 +0000" MODIFIED_BY="Gail Quinn" NAME="De Jaeger 1998" TYPE="JOURNAL_ARTICLE">
<AU>De Jaeger K, Merlo FM, Kavanagh MC, Fyles AW, Hedley D et al</AU>
<TI>Heterogeneity of tumor oxygenation: relationship to tumor necrosis, tumor size, and metastasis</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1998</YR>
<VL>42</VL>
<NO>4</NO>
<PG>717-21</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="Index-Medicus"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dinges-1998" MODIFIED="2009-10-28 14:38:39 +0000" MODIFIED_BY="Gail Quinn" NAME="Dinges 1998" TYPE="JOURNAL_ARTICLE">
<AU>Dinges S, Harder C, Wurm R, Buchali A, Blohmer J, Gellermann J et al</AU>
<TI>Combined treatment of inoperable carcinomas of the uterine cervix with radiotherapy and regional hyperthermia. Results of a phase II trial</TI>
<SO>Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft [et al]</SO>
<YR>1998</YR>
<VL>174</VL>
<NO>10</NO>
<PG>517-21</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="Index-Medicus"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Eifel-1994" MODIFIED="2009-10-28 14:38:48 +0000" MODIFIED_BY="Gail Quinn" NAME="Eifel 1994" TYPE="JOURNAL_ARTICLE">
<AU>Eifel PJ, Morris M, Wharton JT, Oswald MJ</AU>
<TI>The influence of tumor size and morphology on the outcome of patients with FIGO stage IB squamous cell carcinoma of the uterine cervix</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1994</YR>
<VL>29</VL>
<NO>1</NO>
<PG>9-16</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="Index-Medicus"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fatehi-2007" MODIFIED="2009-11-10 13:54:25 +0000" MODIFIED_BY="Gail Quinn" NAME="Fatehi 2007" TYPE="JOURNAL_ARTICLE">
<AU>Fatehi D, Van der Zee J, De Bruijne M, Franckena M, Van Rhoon GC</AU>
<TI>RF-power and temperature data analysis of 444 patients with primary cervical cancer: deep hyperthermia using the Sigma-60 applicator is reproducible</TI>
<SO>International Journal of Hyperthermia</SO>
<YR>2007</YR>
<VL>23</VL>
<PG>623-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Franckena-2008" MODIFIED="2009-11-10 13:54:36 +0000" MODIFIED_BY="Gail Quinn" NAME="Franckena 2008" TYPE="JOURNAL_ARTICLE">
<AU>Franckena M, Stalpers L J, Koper P C, Wiggenraad R G, Hoogenraad W J, van Dijk J D et al</AU>
<TI>Long-term improvement in treatment outcome after radiotherapy and hyperthermia in locoregionally advanced cervix cancer: an update of the Dutch Deep Hyperthermia Trial</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>2008</YR>
<VL>70</VL>
<NO>4</NO>
<PG>1176-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fyles-1995" MODIFIED="2009-10-28 14:40:05 +0000" MODIFIED_BY="Gail Quinn" NAME="Fyles 1995" TYPE="JOURNAL_ARTICLE">
<AU>Fyles AW, Pintilie M, Kirkbride P, Levin W, Manchul LA, Rawlings GA</AU>
<TI>Prognostic factors in patients with cervix cancer treated by radiation therapy: results of a multiple regression analysis</TI>
<SO>Radiotherapy and Oncology Journal of the European Society for Therapeutic Radiology and Oncology</SO>
<YR>1995</YR>
<VL>35</VL>
<NO>2</NO>
<PG>107-17</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="Index-Medicus"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fyles-1998" MODIFIED="2009-10-28 14:40:16 +0000" MODIFIED_BY="Gail Quinn" NAME="Fyles 1998" TYPE="JOURNAL_ARTICLE">
<AU>Fyles AW, Milosevic M, Wong R, Kavanagh MC, Pintilie M, Sun A et al</AU>
<TI>Oxygenation predicts radiation response and survival in patients with cervix cancer</TI>
<SO>Radiotherapy and Oncology Journal of the European Society for Therapeutic Radiology and Oncology</SO>
<YR>1998</YR>
<VL>48</VL>
<NO>2</NO>
<PG>149-56</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="Index-Medicus"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gellermann-2005" MODIFIED="2009-10-28 14:40:37 +0000" MODIFIED_BY="Gail Quinn" NAME="Gellermann 2005" TYPE="JOURNAL_ARTICLE">
<AU>Gellermann J, Wlodarczyk W, Ganter H, Nadobny J, Fähling H, Seebass M et al</AU>
<TI>A practical approach to perform the thermography in a hyperthermia/MR hybrid system - validation in an anthropomorphous phantom</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>2005</YR>
<VL>61</VL>
<PG>267-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Haensgen-2001" MODIFIED="2009-10-28 14:40:49 +0000" MODIFIED_BY="Gail Quinn" NAME="Haensgen 2001" TYPE="JOURNAL_ARTICLE">
<AU>Haensgen G, Krause U, Becker A, Stadler P, Lautenschlaeger C, Wohlrab W et al</AU>
<TI>Tumor hypoxia, p53, and prognosis in cervical cancers</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>2001</YR>
<VL>50</VL>
<NO>4</NO>
<PG>865-72</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="Index-Medicus"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Haie-1988" MODIFIED="2009-10-28 14:41:19 +0000" MODIFIED_BY="Gail Quinn" NAME="Haie 1988" TYPE="JOURNAL_ARTICLE">
<AU>Haie C, Pejovic MH, Gerbaulet A, Horiot JC, Pourquier H, Delouche J et al</AU>
<TI>Is prophylactic para-aortic irradiation worthwhile in the treatment of advanced cervical carcinoma? Results of a controlled clinical trial of the EORTC radiotherapy group</TI>
<SO>Radiotherapy and Oncology Journal of the European Society for Therapeutic Radiology and Oncology</SO>
<YR>1988</YR>
<VL>11</VL>
<NO>2</NO>
<PG>101-12</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="Index-Medicus"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2009-10-12 15:49:15 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2008" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of interventions Version 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hiraki-2000" MODIFIED="2010-02-08 12:03:34 +0000" MODIFIED_BY="Gail Quinn" NAME="Hiraki 2000" TYPE="JOURNAL_ARTICLE">
<AU>Hiraki Y, Nakajo M, Takeshita T, Churei H</AU>
<TI>The size and distance of the opposite flat applicator change the SAR and thermal distributions of RF capacitive intracavitary hyperthermia</TI>
<SO>International Journal of Hyperthermia</SO>
<YR>2000</YR>
<VL>16</VL>
<PG>205-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hockel-1993" MODIFIED="2009-10-28 14:42:00 +0000" MODIFIED_BY="Gail Quinn" NAME="Hockel 1993" TYPE="JOURNAL_ARTICLE">
<AU>Hockel M, Knoop C, Schlenger K, Vorndran B, Baussmann E, Mitze M et al</AU>
<TI>Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix</TI>
<SO>Radiotherapy and Oncology Journal of the European Society for Therapeutic Radiology and Oncology</SO>
<YR>1993</YR>
<VL>26</VL>
<NO>1</NO>
<PG>45-50</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="Index-Medicus"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hockel-1999" MODIFIED="2009-10-28 14:42:08 +0000" MODIFIED_BY="Gail Quinn" NAME="Hockel 1999" TYPE="JOURNAL_ARTICLE">
<AU>Hockel M, Schlenger K, Hockel S, Vaupel P</AU>
<TI>Hypoxic cervical cancers with low apoptotic index are highly aggressive</TI>
<SO>Cancer Research</SO>
<YR>1999</YR>
<VL>59</VL>
<NO>18</NO>
<PG>4525-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="Index-Medicus"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Horiot-1988" MODIFIED="2009-10-28 14:42:20 +0000" MODIFIED_BY="Gail Quinn" NAME="Horiot 1988" TYPE="JOURNAL_ARTICLE">
<AU>Horiot JC, Pigneux J, Pourquier H, Schraub S, Achille E, Keiling R et al</AU>
<TI>Radiotherapy alone in carcinoma of the intact uterine cervix according to G. H. Fletcher guidelines: a French cooperative study of 1383 cases</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1988</YR>
<VL>14</VL>
<NO>4</NO>
<PG>605-11</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="Index-Medicus"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Khalil-1995" MODIFIED="2009-10-28 14:53:10 +0000" MODIFIED_BY="Gail Quinn" NAME="Khalil 1995" TYPE="JOURNAL_ARTICLE">
<AU>Khalil AA, Horsman MR, Overgaard J</AU>
<TI>The importance of determining necrotic fraction when studying the effect of tumour volume on tissue oxygenation</TI>
<SO>Acta Oncologica Stockholm (Stockholm, Sweden)</SO>
<YR>1995</YR>
<VL>34</VL>
<NO>3</NO>
<PG>297-300</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="Index-Medicus"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lanciano-1991" MODIFIED="2009-10-28 14:53:19 +0000" MODIFIED_BY="Gail Quinn" NAME="Lanciano 1991" TYPE="JOURNAL_ARTICLE">
<AU>Lanciano RM, Won M, Coia LR, Hanks GE</AU>
<TI>Pretreatment and treatment factors associated with improved outcome in squamous cell carcinoma of the uterine cervix: a final report of the 1973 and 1978 patterns of care studies</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1991</YR>
<VL>20</VL>
<NO>4</NO>
<PG>667-76</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="Ca15978canci; cm87275cmnci"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mendenhall-1984" MODIFIED="2009-10-28 14:53:31 +0000" MODIFIED_BY="Gail Quinn" NAME="Mendenhall 1984" TYPE="JOURNAL_ARTICLE">
<AU>Mendenhall WM, Thar TL, Bova FJ, Marcus RB, Jr., Morgan LS, Million RR</AU>
<TI>Prognostic and treatment factors affecting pelvic control of Stage IB and IIA-B carcinoma of the intact uterine cervix treated with radiation therapy alone</TI>
<SO>Cancer</SO>
<YR>1984</YR>
<VL>53</VL>
<NO>12</NO>
<PG>2649-54</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="Abridged-Index-Medicus; Index-Medicus"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Milross-1997" MODIFIED="2009-10-28 14:53:59 +0000" MODIFIED_BY="Gail Quinn" NAME="Milross 1997" TYPE="JOURNAL_ARTICLE">
<AU>Milross CG, Tucker SL, Mason KA, Hunter NR, Peters LJ, Milas L</AU>
<TI>The effect of tumor size on necrosis and polarographically measured pO2</TI>
<SO>Acta Oncologica Stockholm, Sweden</SO>
<YR>1997</YR>
<VL>36</VL>
<NO>2</NO>
<PG>183-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="Ca06294canci"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Parmar-1998" MODIFIED="2009-10-28 14:54:21 +0000" MODIFIED_BY="Gail Quinn" NAME="Parmar 1998" TYPE="JOURNAL_ARTICLE">
<AU>Parmar M K, Torri V, Stewart L</AU>
<TI>Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints</TI>
<SO>Statistics in Medicine</SO>
<YR>1998</YR>
<VL>17</VL>
<NO>24</NO>
<PG>2815-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Perez-1998" MODIFIED="2009-10-28 14:54:32 +0000" MODIFIED_BY="Gail Quinn" NAME="Perez 1998" TYPE="JOURNAL_ARTICLE">
<AU>Perez CA, Grigsby PW, Chao KS, Mutch DG, Lockett MA</AU>
<TI>Tumor size, irradiation dose, and long-term outcome of carcinoma of uterine cervix</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1998</YR>
<VL>41</VL>
<NO>2</NO>
<PG>307-17</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="Index-Medicus"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rhee-1991" MODIFIED="2009-11-10 13:55:48 +0000" MODIFIED_BY="Gail Quinn" NAME="Rhee 1991" TYPE="JOURNAL_ARTICLE">
<AU>Rhee JG, Lee CKK, Osborn J, Levitt SH, Song CW</AU>
<TI>Precooling prevents overheating of subcutaneous fat in the use of RF capacitive heating</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1991</YR>
<VL>20</VL>
<PG>1009-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rotman-1995" MODIFIED="2009-11-10 13:48:44 +0000" MODIFIED_BY="Gail Quinn" NAME="Rotman 1995" TYPE="JOURNAL_ARTICLE">
<AU>Rotman M, Pajak TF, Choi K, Clery M, Marcial V, Grigsby PW et al</AU>
<TI>Prophylactic extended-field irradiation of para-aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas. Ten-year treatment results of RTOG 79-20</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>274</VL>
<NO>5</NO>
<PG>387-93</PG>
<IDENTIFIERS MODIFIED="2009-11-10 13:48:44 +0000" MODIFIED_BY="Gail Quinn">
<IDENTIFIER TYPE="OTHER" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rubin-1995" MODIFIED="2009-11-10 13:48:31 +0000" MODIFIED_BY="Gail Quinn" NAME="Rubin 1995" TYPE="JOURNAL_ARTICLE">
<AU>Rubin P, Constine LS, Fajardo LF</AU>
<TI>RTOG Late Effects Working Group. Overview. Late Effects of Normal Tissues (LENT) scoring system</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1995</YR>
<VL>31</VL>
<PG>1041-2</PG>
<IDENTIFIERS MODIFIED="2009-11-10 13:48:31 +0000" MODIFIED_BY="Gail Quinn"/>
</REFERENCE>
<REFERENCE ID="REF-Sreenivasa-2003" MODIFIED="2009-10-28 14:55:09 +0000" MODIFIED_BY="Gail Quinn" NAME="Sreenivasa 2003" TYPE="JOURNAL_ARTICLE">
<AU>Sreenivasa G, Gellermann J, Rau R, Nadobny J, Schlag P, Deuflhard P et al</AU>
<TI>Clinical application of the hyperthermia treatment planning system HyperPlan - comparison of algorithms and clinical observables</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>2003</YR>
<VL>55</VL>
<PG>407-419</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stehman-1991" MODIFIED="2009-10-28 14:55:20 +0000" MODIFIED_BY="Gail Quinn" NAME="Stehman 1991" TYPE="JOURNAL_ARTICLE">
<AU>Stehman FB, Bundy BN, DiSaia PJ, Keys HM, Larson JE, Fowler WC</AU>
<TI>Carcinoma of the cervix treated with radiation therapy. I. A multi-variate analysis of prognostic variables in the Gynecologic Oncology Group</TI>
<SO>Cancer</SO>
<YR>1991</YR>
<VL>67</VL>
<NO>11</NO>
<PG>2776-85</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="Ca12534canci; ca27816canci; ca12484canci"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Stehman-1994" MODIFIED="2009-10-28 14:55:29 +0000" MODIFIED_BY="Gail Quinn" NAME="Stehman 1994" TYPE="JOURNAL_ARTICLE">
<AU>Stehman FB, Thomas GM</AU>
<TI>Prognostic factors in locally advanced carcinoma of the cervix treated with radiation therapy</TI>
<SO>Seminars in Oncology</SO>
<YR>1994</YR>
<VL>21</VL>
<NO>1</NO>
<PG>25-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="Index-Medicus"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Thomas-2001" MODIFIED="2009-10-28 14:55:42 +0000" MODIFIED_BY="Gail Quinn" NAME="Thomas 2001" TYPE="JOURNAL_ARTICLE">
<AU>Thomas G</AU>
<TI>The effect of hemoglobin level on radiotherapy outcomes: the Canadian experience</TI>
<SO>Seminars in Oncology</SO>
<YR>2001</YR>
<VL>28</VL>
<NO>2 Suppl 8</NO>
<PG>60-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="Index-Medicus"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tierney-2004" MODIFIED="2009-10-28 14:52:58 +0000" MODIFIED_BY="Gail Quinn" NAME="Tierney 2004" TYPE="OTHER">
<AU>Tierney JF, Sydes MR</AU>
<TI>HR calculations spreadsheet</TI>
<SO>http://www.biomedcentral.com/content/supplementary/1745-6215-8-16-S1.xls</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tierney-2007" MODIFIED="2009-10-23 13:58:58 +0100" MODIFIED_BY="[Empty name]" NAME="Tierney 2007" TYPE="JOURNAL_ARTICLE">
<AU>Tierney JF, Stewart LA, Ghersi D, Burdett S and Sydes MR</AU>
<TI>Practical methods for incorporating summary time-to-event data into meta-analysis</TI>
<SO>Trials</SO>
<YR>2007</YR>
<VL>8</VL>
<NO>16</NO>
<PG>1-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tsang-1995" MODIFIED="2009-10-28 14:56:02 +0000" MODIFIED_BY="Gail Quinn" NAME="Tsang 1995" TYPE="JOURNAL_ARTICLE">
<AU>Tsang RW, Fyles AW, Kirkbride P, Levin W, Manchul LA, Milosevic MF et al</AU>
<TI>Proliferation measurements with flow cytometry Tpot in cancer of the uterine cervix: correlation between two laboratories and preliminary clinical results</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1995</YR>
<VL>32</VL>
<NO>5</NO>
<PG>1319-29</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="Index-Medicus"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-van-der-Zee-2005" MODIFIED="2009-10-28 14:56:15 +0000" MODIFIED_BY="Gail Quinn" NAME="van der Zee 2005" TYPE="OTHER">
<AU>Van der Zee J, Van Rhoon GC, Wust P</AU>
<TI>Letter to the editor. In regard to dr. Vasanthan et al</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>2005</YR>
<VL>62</VL>
<NO>940-41</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-van-der-Zee-2008" MODIFIED="2009-10-28 14:56:24 +0000" MODIFIED_BY="Gail Quinn" NAME="van der Zee 2008" TYPE="JOURNAL_ARTICLE">
<AU>Van der Zee J, Vujaskovic Z, Kondo M, Sugahara T</AU>
<TI>The Kadota Fund International Forum 2004 - Clinical group consensus</TI>
<SO>International Journal of Hyperthermia</SO>
<YR>2008</YR>
<VL>24</VL>
<PG>111-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vaupel-2001" MODIFIED="2009-10-28 14:56:35 +0000" MODIFIED_BY="Gail Quinn" NAME="Vaupel 2001" TYPE="JOURNAL_ARTICLE">
<AU>Vaupel P, Kelleher DK, Hockel M</AU>
<TI>Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy</TI>
<SO>Seminars in Oncology</SO>
<YR>2001</YR>
<VL>28</VL>
<NO>2 Suppl 8</NO>
<PG>29-35</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="Index-Medicus"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Werner-1995" MODIFIED="2009-10-28 14:56:55 +0000" MODIFIED_BY="Gail Quinn" NAME="Werner 1995" TYPE="JOURNAL_ARTICLE">
<AU>Werner WM, Schmid CH, Bornstein L, Ball HG, Smith DM, Madoc Jones H</AU>
<TI>Prognostic factors for local and distant recurrence in stage I and II cervical carcinoma</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1995</YR>
<VL>32</VL>
<NO>5</NO>
<PG>1309-17</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="Index-Medicus"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-West-1995" MODIFIED="2009-10-28 14:57:16 +0000" MODIFIED_BY="Gail Quinn" NAME="West 1995" TYPE="JOURNAL_ARTICLE">
<AU>West CM, Davidson SE, Burt PA, Hunter RD</AU>
<TI>The intrinsic radiosensitivity of cervical carcinoma: correlations with clinical data</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1995</YR>
<VL>31</VL>
<NO>4</NO>
<PG>841-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="Index-Medicus"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-WHO-1979" MODIFIED="2009-11-10 13:40:15 +0000" MODIFIED_BY="Gail Quinn" NAME="WHO 1979" TYPE="BOOK">
<AU>WHO</AU>
<SO>The WHO handbook for reporting results of cancer treatment</SO>
<YR>1979</YR>
<PB>WHO</PB>
<CY>Geneva</CY>
<IDENTIFIERS MODIFIED="2009-03-03 09:05:33 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2010-01-28 13:19:44 +0000" MODIFIED_BY="Gail Quinn">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2010-01-28 13:19:44 +0000" MODIFIED_BY="Gail Quinn" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2009-10-22 18:49:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chen-1997">
<CHAR_METHODS MODIFIED="2009-10-22 18:49:38 +0100" MODIFIED_BY="[Empty name]">
<P>Single centre RCT (arms = 4 )<BR/>randomisation procedure: adequate, ITT: unknown, baseline characteristics similar: unknown, eligibility criteria specified: yes, losses to follow up fully accounted for: unknown, bias due withdrawal/drop-out rate: unknown, co-interventions influenced results: no<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-10-05 15:38:33 +0100" MODIFIED_BY="[Empty name]">
<P>Cervical cancer patients: E: 30, C: 30. <BR/>FIGO stage: IIB (E:7, C:7);IIIB (E:23, C: 23)<BR/>Age: E: unknown (32-70), C: unknown (32-70)<BR/>WHO performance:0-1<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-10-05 15:38:33 +0100" MODIFIED_BY="[Empty name]">
<P>HT: Vaginal applicators. Timing: from the second week of EBRT. Duration: 45 minutes. Sequence: 1 hour after EBRT. Frequency:twice weekly with 48 to 72 hour interval. Total number: 6. <BR/>RT: Standard EBRT: linear accelerator or telecobalt. Two parallel opposed fields. Primary tumour and pelvic draining lymphatics. A total dose of 20 Gy in 10 fractions in 2 weeks and an additional dose of 20 Gy in 10 fractions with a central block. <BR/>Brachytherapy: Co-60. Timing: From the second week of EBRT. Dose per fraction: 5 to 10 Gy to 'Point A'. Frequency: weekly. Total number: 5-6. <BR/>CT: yes (groups were not included in analysis)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-10-05 15:38:34 +0100" MODIFIED_BY="[Empty name]">
<P>CR (end of treatment)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-11-12 13:40:08 +0000" MODIFIED_BY="Clare Jess">
<P>2 arms (n = 60) with CT were not included in review<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-10-05 15:38:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Datta-1987">
<CHAR_METHODS MODIFIED="2009-04-20 18:57:55 +0100" MODIFIED_BY="[Empty name]">
<P>Multi centre RCT (arms = 2, centre = 3 )<BR/>randomisation procedure: unknown, ITT:no, baseline characteristics similar: unknown, eligibility criteria specified: yes, losses to follow up fully accounted for: yes, bias due with-drawal/drop-out rate: no, co-interventions influenced results: no<BR/>Total quality score: 2<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-10-05 15:38:34 +0100" MODIFIED_BY="[Empty name]">
<P>Cervical cancer patients: E: 33, C: 31. <BR/>FIGO stage IIIB. Histology: squamous cell carcinoma: 64.<BR/>Age: E: unknown (33-67), C: unknown (28-74)<BR/>WHO performance:unknown</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-10-05 15:38:34 +0100" MODIFIED_BY="[Empty name]">
<P>HT: Capacitative applicators consisting of 2 plates. Duration: 15-20 minutes. Sequence: immediately preceding EBRT. Frequency: twice weekly with 72 hour interval. Total number: unknown. <BR/>RT: Standard EBRT: telecobalt. Four field box-technique. Primary tumour and pelvic draining lymphatics. Total dose of 50 to 55 Gy in 25 to 28 fractions in 5 to 5½ weeks. An additional dose to the local tumour using antero-posterior opposed fields delivering a 10-15 Gy in 5-8 fractions in 1-1½ week. <BR/>Brachytherapy: no<BR/>CT: no</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-10-05 15:38:34 +0100" MODIFIED_BY="[Empty name]">
<P>CR (4 weeks after treatment)<BR/>LR (2Y)<BR/>DFS (2Y) </P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-10-05 15:38:34 +0100" MODIFIED_BY="[Empty name]">
<P>No details on statistical analysis.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-10-22 18:49:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Harima-2001">
<CHAR_METHODS MODIFIED="2009-10-22 18:49:17 +0100" MODIFIED_BY="[Empty name]">
<P>single centre RCT (arms = 2)<BR/>randomisation procedure: adequate, ITT: unknown, baseline characteristics similar: yes, eligibility criteria specified: yes, losses to follow up fully accounted for: yes, bias due withdrawal/drop-out rate: no, co-interventions influenced results: no<BR/>Total quality score:4</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-10-05 15:38:34 +0100" MODIFIED_BY="[Empty name]">
<P>Cervical cancer patients: E: 20, C: 20<BR/>FIGO stage IIIB (n=40)<BR/>Histology: Squamous cell carcinoma (n=35); Adenocarcinoma (n=5).</P>
<P> Tumour diameter (mean): E 5.9 (+/- 2.2), C; 6.1 (+/- 1.8)</P>
<P>Age: E: 64.9 (unknown), C: 61.6 (unknown)<BR/>WHO performance: unknown</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-10-05 15:38:34 +0100" MODIFIED_BY="[Empty name]">
<P>HT: Capacitative applicators with 2 plates. Timing: after 3rd of 4th fraction of EBRT. Duration: 60 minutes. Sequence: within 30 minutes after EBRT. Frequency: once weekly. Total number: 3. <BR/>RT: Standard EBRT: 6 MV linear accelerator. No details provided concerning radiation technique. Primary tumour and pelvic draining lymphatics. Total dose of 30.6 Gy in 17 fractions of 1.8 Gy, 5 times a week, with an additional dose of 52.2 Gy to the parametria with central shielding. EBRT to primary tumour and lymphatics 30.6 Gy/ 17 f, additional dose central block 52.2 Gy<BR/>Brachytherapy: Ir-192 (High Dose Rate). Timing: unknown. Dose per fraction: 7.5 Gy to 'Point A'. Frequency: once weekly during EBRT. Total number: 4.<BR/>CT: no</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-10-05 15:38:35 +0100" MODIFIED_BY="[Empty name]">
<P>CR (at least 1 month after treatment)</P>
<P>LR (3Y)<BR/>DFS (3Y)<BR/>
<BR/>OS (3Y)<BR/>TOX acute and late</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-10-22 18:49:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sharma-1991">
<CHAR_METHODS MODIFIED="2009-10-22 18:49:11 +0100" MODIFIED_BY="[Empty name]">
<P>single centre RCT (arms = 2 )<BR/>randomisation procedure: adequate, ITT: no, baseline characteristics similar: yes, eligibility criteria specified: yes, losses to follow up fully accounted for: yes, bias due withdrawal/drop-out rate: no,<BR/>co-interventions influenced results: no<BR/>Total quality score: 4</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-10-05 15:38:35 +0100" MODIFIED_BY="[Empty name]">
<P>Cervical cancer patients: E: 25, C: 25<BR/>FIGO stage IIA (n=3); IIB (n=4) andIIIB (n=43)</P>
<P>Histology: squamous cell carcinoma (n=50)</P>
<P>Tumour diameter: 2-4 cm (E: 7; C 6); &gt;4 cm (E: 18; C 19)</P>
<P>Age: E: 50 (unknown), C: 48 (unknown)<BR/>Karnofsky &gt; 60</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-10-05 15:38:35 +0100" MODIFIED_BY="[Empty name]">
<P>HT: Specially designed capacitative intraluminal radiofrequency heating system, consisting of a small intravaginal applicator and a large extracorporeal electrode. Timing: from start of EBRT. Duration: 30 minutes. Sequence: within 30 minutes preceding EBRT. Frequency: on alternate days 3 times per week. Total number: 12. <BR/>RT: Standard EBRT: linear accelerator or telecobalt. Two parallel opposed fields. Primary tumour and pelvic draining lymphatics. Total dose 45 Gy in 20 fractions in 4 weeks. If brachytherapy not feasible an additional EBRT dose of 20 Gy in 10 fractions using same fields. <BR/>Brachytherapy: if feasible. Cs-137 (Low Dose Rate). Timing: following EBRT. Dose per fraction: 35 Gy to 'Point A' . Total number: 1.<BR/>CT: no</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-10-05 15:38:35 +0100" MODIFIED_BY="[Empty name]">
<P>LR (18 MO)</P>
<P>DFS (18 MO)</P>
<P>OS (18 MO)<BR/>TOX acute and late<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-04-23 15:34:45 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-10-22 18:48:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-van-der-Zee-2000">
<CHAR_METHODS MODIFIED="2009-10-22 18:48:58 +0100" MODIFIED_BY="[Empty name]">
<P>Multi centre RCT (arms = 2, centre = 9 )<BR/>randomisation procedure: adequate, ITT: yes, baseline characteristics similar: yes, eligibility criteria specified: yes, losses to follow up fully accounted for: yes, bias due withdrawal/drop-out rate: no, co-interventions influenced results: no<BR/>Total quality score: 5</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-10-05 15:38:35 +0100" MODIFIED_BY="[Empty name]">
<P>Cervical cancer patients: E: 58, C: 56<BR/>FIGO stage IIB (n=22); IIIA (n=1); IIIB (n=80) and IVA (n=11).</P>
<P>Histology: squamous cell carcinoma (n=97); adenocarcinoma (n=11); other (n=6)</P>
<P>Tumour diameter: &lt; 6cm (E 13; C 12); 6-8 cm (E 26; C 27); &gt; 8 cm (E 19; C 13); unknown (E 0; C 4).<BR/>Age: E: 51 (26-75), C: 50 (30-82)<BR/>WHO performance:&lt;2</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-10-05 15:38:35 +0100" MODIFIED_BY="[Empty name]">
<P>HT: Regional (deep) hyperthermia was applied in 3 different centres using the BSD-2000 system, the 4-waveguide applicator system and the coaxial TEM applicator, respectively. Timing: from the first week of EBRT on. Frequency: once weekly. Duration: 60-90 minutes. Sequence: 1-4 hours after EBRT. Total number: 0 (n=7);1-3 (n=11) and 4-6 (n=40). <BR/>RT: Standard EBRT: linear accelerator. No details concerning radiation technique. Primary tumour and pelvic draining lymphatics with or without the para-aortic lymph nodes. Total dose 46-50.4 Gy in 23-28 fractions. An additional dose to the pelvic sidewall was delivered in case of residual parametric tumour. If brachytherapy was not feasible an additional dose with EBRT was delivered to the tumour region. EBRT to primary tumour and lymphatics 46-50.4 Gy/ 23-28 f<BR/>Brachytherapy: if feasible.(1) Ir-192 (High Dose Rate; n=38); Timing: following EBRT. Dose per fraction: 8.5 Gy to 'Point A'. Frequency: weekly. Total number: 2. (2) Cs-137 (Low Dose Rate; n=53); Timing: following EBRT. Dose per fraction: 20-30 Gy to 'Point A'.<BR/>CT: no</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-10-05 15:38:36 +0100" MODIFIED_BY="[Empty name]">
<P>
<BR/>CR (at least 1 month after treatment)</P>
<P>LR (3Y)</P>
<P>OS (3Y)<BR/>TOX acute and late<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-10-22 18:50:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vasanthan-2005">
<CHAR_METHODS MODIFIED="2009-10-22 18:50:06 +0100" MODIFIED_BY="[Empty name]">
<P>Multi centre RCT (arms = 2, centre = 5 )<BR/>randomisation procedure: adequate, ITT: yes, baseline characteristics similar: yes, eligibility criteria specified: yes, losses to follow up fully accounted for: yes, bias due withdrawal/drop-out rate: no<BR/>co-interventions influenced results: no<BR/>Total quality score: 5</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-10-05 15:38:36 +0100" MODIFIED_BY="[Empty name]">
<P>Cervical cancer patients: E: 55, C: 55<BR/>Figo stage IIB (n=56); IIIA (n=9); IIIB (n=42) and IVA (n=3).</P>
<P>Histology: squamous cell carcinoma (n=103); adenocarcinoma (n=4); other (n=3).</P>
<P>Tumour volume (median): E: 60 cm<SUP>3</SUP> ; C 50 cm<SUP>3.</SUP> <BR/>Age: E: 45 (27-72), C: 50 (22-71)<BR/>WHO performance:&lt;2<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-10-05 15:38:37 +0100" MODIFIED_BY="[Empty name]">
<P>HT: Capacitative applicators with 2 plates were used for generating local hyperthermia. In at least half of the patients this was combined with an intravaginal electrode. Protocols varied per centre. Timing: not available. Frequency: once weekly. Duration: 60 minutes. Sequence: immediately after EBRT (three centres); immediately before EBRT (one centre) Not available (one centre). Total number: 3-6. </P>
<P>
<BR/>RT: Standard EBRT: 6-18 MV linear accelerator or telecobalt. Primary tumour and pelvic lymphatics. </P>
<P>(n = 54) <BR/>
</P>
<P>A total EBRT dose of 50 Gy in 2 Gy fractions in 5 weeks. Four field box technique. Two patients received an additional EBRT dose of 20 Gy instead of brachytherapy. Brachytherapy: Low Dose Rate. Timing: following EBRT. Dose per fraction: 20-22 Gy to 'Point A'. Total number: 1.</P>
<P>(n = 28) </P>
<P>A total EBRT dose of 14-18 Gy in 2 Gy fractions followed by an additional dose of 24-32 Gy using central shielding. Parallel opposed fields. Brachytherapy: High Dose Rate. Timing: unavailable. Dose per fraction: 5 Gy to 'Point A'. Frequency: unknown. Total number: 10. </P>
<P>(n = 18) <BR/>
</P>
<P>A total EBRT dose of 50.4 Gy in 1.8 to 2 Gy fractions, in 5 to 6 weeks. Four field box technique. An additional parametrial boost of 5.4 Gy in 3 fractions with central shielding. Brachytherapy: Co-60 (High Dose Rate). Timing: following EBRT dose of 50.4 Gy. Dose per fraction: 3 Gy to 'Point A'. Frequency: 3 times weekly. Total number: 7-13. </P>
<P>(n = 9) </P>
<P>A total EBRT dose of 30 Gy in 2 Gy fractions, 5 times a week followed by an additional dose of 20 Gy with central shielding. Four field box or parallel opposed fields. Brachytherapy: High Dose Rate. Timing: concomitantly with EBRT. Dose per fraction: 6 Gy to 'point A'. </P>
<P>(n = 1) EBRT to primary tumour and lymphatics 30 Gy/wk, Brachytherapy:</P>
<P>A total EBRT dose of 30 Gy in 2 Gy fractions. Brachytherapy: High Dose Rate. Timing: unavailable. Dose per fraction: 6 Gy to 'point A'. Frequency: twice weekly. Total number: 4. </P>
<P>
<BR/>CT: no</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-10-05 15:38:37 +0100" MODIFIED_BY="[Empty name]">
<P>
<BR/>LR (3Y)<BR/>OS (3Y)</P>
<P>TOX acute and late<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>
<LINK REF="FIG-08" TYPE="FIGURE">Figure 8</LINK>
</P>
<P>
<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2008-11-12 13:40:49 +0000" MODIFIED_BY="Clare Jess" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-El-Sharouni-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>no RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fujiwara-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>no RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gupta-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>no RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hasegawa-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>no RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hornback-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>no RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kohno-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>no RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Li-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>not able to contact author</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Prosnitz-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT, ongoing</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>RCT = Randomized clinical trial</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2009-10-22 12:03:49 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2009-10-22 18:06:08 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2009-04-20 18:56:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Harima">
<CHAR_STUDY_NAME MODIFIED="2009-04-20 18:56:15 +0100" MODIFIED_BY="[Empty name]">
<P>Multicenter trial (6 centres)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>Cervical cancer<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>RT+HT <BR/>RT+ CT <BR/>RT+HT+ CT</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>unknown</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>unknown</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Department of Radiology, Kansai Medical University, Moriguchi, Osaka 570-8507, Japan.<BR/>Y. Harima, principal investigator<BR/>Email: harima@takii.kmu.ac.jp<BR/>
</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>closed after inclusion 62 pts,</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2009-10-22 18:06:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Piotrkowicz">
<CHAR_STUDY_NAME/>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>Cervical cancer<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>RT<BR/>RT + HT (Int)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>side effects<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>01-11-06</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2009-10-22 18:06:08 +0100" MODIFIED_BY="[Empty name]">
<P>Brachytherapy dept.<BR/>N. Piotrkowicz , principal investigator<BR/>Center Oncology M.S.C. Memorial Institute<BR/>Warsaw, Poland<BR/>
</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2009-10-19 15:58:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Prosnitz">
<CHAR_STUDY_NAME>
<P>Cisplatin and Radiation Therapy With or Without Hyperthermia Therapy in Treating Patients With Cervical Cancer</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS MODIFIED="2008-11-12 13:40:50 +0000" MODIFIED_BY="Clare Jess">
<P>Cervical cancer (n = 400)<BR/>Figo Stage IIB-IVA<BR/>Figo Stage IA, IB, or IIA with positive pelvic lymph nodes or parametria by imaging OR pathologically involved at time of surgery<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>RT+ CT<BR/>RT+ CT+ HT</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>LRC<BR/>failure-free survival<BR/>OS</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>01-06-04</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2009-10-19 15:58:16 +0100" MODIFIED_BY="[Empty name]">
<P>Dr. A.M. Westermann<BR/>Afdeling Medische Oncologie<BR/>Academisch Medisch Centrum AMC<BR/>Universiteit van Amsterdam)<BR/>Meibergdreef 9<BR/>1105 AZ Amsterdam<BR/>
<BR/>Postadres<BR/>AMC<BR/>Postbus 22660<BR/>1100 DD Amsterdam</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2009-10-05 15:38:37 +0100" MODIFIED_BY="[Empty name]">
<P>Phase III<BR/>update of Phase II Westerman et al.<BR/>
</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2009-10-05 15:38:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-RADCHOC">
<CHAR_STUDY_NAME>
<P>RADCHOC</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS MODIFIED="2009-10-05 15:38:37 +0100" MODIFIED_BY="[Empty name]">
<P>376 cervical cancer<BR/>figo stage IB-IIA (&gt; similar to 4 CM and IIB-IVA)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>RT + HT (Reg)<BR/>RT + CT</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>EFS<BR/>LRC<BR/>OS<BR/>QoL<BR/>Costs</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>24-11-03</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Erasmus MC - Daniel den Hoed Cancer Center<BR/>Cobi van der Zee, MD,PhD, Cobi van der Zee<BR/>P.O. Box 5201, Rotterdam, The Netherlands<BR/>Ph: *31 10 7041470<BR/>Email: j.vanderzee@erasmusmc.nl</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<FOOTNOTES>
<P>RT = radiotherapy, HT = Hyperthermia, Reg = regional, Int = interstitial, CT = , TOX acute = toxicity acute , TOX late = Toxicity late, EFS = Event Free Survival , LRC = LocoRegional Control, OS = Overall Survival, QoL = Quality of Life, pts = patients, CisPt = cisplatin,</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2010-01-28 13:19:44 +0000" MODIFIED_BY="Gail Quinn">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2009-10-22 18:49:31 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-22 18:49:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chen-1997">
<DESCRIPTION>
<P>Quote: "A randomised Trial". </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-22 18:49:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Datta-1987">
<DESCRIPTION>
<P>Quote: "All cases were randomised and divided into two groups".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-22 18:06:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Harima-2001">
<DESCRIPTION>
<P>Quote: "Randomization to treatment groups". </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-22 18:48:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sharma-1991">
<DESCRIPTION>
<P>Quote: "The patients were randomised blindly into 2 groups of 25 each". </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-22 18:06:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vasanthan-2005">
<DESCRIPTION>
<P>Quote: "Patients were registered and randomized".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-22 18:06:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-der-Zee-2000">
<DESCRIPTION>
<P>Quote: "Patients were randomly assigned treatment". </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2009-10-22 18:49:27 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-22 18:49:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chen-1997">
<DESCRIPTION>
<P>Quote: "The patients were orderly grouped according to clinical stages". Taken the fact that it is a randomised trial this probably refers to a stratification procedure although this is not clear from the text.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-22 18:06:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Datta-1987">
<DESCRIPTION>
<P> Insufficiently described. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-22 18:06:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Harima-2001">
<DESCRIPTION>
<P> Quote: "Randomization was performed by a computer generated random number list before the start of treatment". </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-22 18:48:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sharma-1991">
<DESCRIPTION>
<P> For randomisation the sealed envelope technique was used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-22 18:06:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vasanthan-2005">
<DESCRIPTION>
<P>Probably central allocation since (quote) "patients were stratified by institution".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-22 18:06:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-der-Zee-2000">
<DESCRIPTION>
<P>Quote: "Randomisation was done centrally by telephone and stratified by centre, tumour site and stage in variable block size".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2009-10-22 18:06:08 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-10-22 18:06:05 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Chen-1997">
<DESCRIPTION>
<P>No blinding. However, the outcome measurements are not likely to be influenced.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-10-22 18:06:05 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Datta-1987">
<DESCRIPTION>
<P>No blinding. However, the outcome measurements are not likely to be influenced.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-10-22 18:06:05 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Harima-2001">
<DESCRIPTION>
<P>No blinding. However, the outcome measurements are not likely to be influenced.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-10-22 18:06:06 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sharma-1991">
<DESCRIPTION>
<P>No blinding. However, the outcome measurements are not likely to be influenced.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-10-22 18:06:08 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Vasanthan-2005">
<DESCRIPTION>
<P>No blinding. However, the outcome measurements are not likely to be influenced.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-10-22 18:06:07 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-van-der-Zee-2000">
<DESCRIPTION>
<P>No blinding. However, the outcome measurements are not likely to be influenced.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2010-01-28 13:19:44 +0000" MODIFIED_BY="Gail Quinn" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-01-28 13:19:44 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Chen-1997">
<DESCRIPTION>
<P>There were no missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-01-28 13:19:44 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Datta-1987">
<DESCRIPTION>
<P>The number of missing outcome data is equally distributed across the intervention groups with similar reasons for missing</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-10-22 18:06:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Harima-2001">
<DESCRIPTION>
<P>There were no missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-01-28 13:19:44 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Sharma-1991">
<DESCRIPTION>
<P>There were no missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-01-28 13:19:44 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Vasanthan-2005">
<DESCRIPTION>
<P>There were no missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-10-22 18:06:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-der-Zee-2000">
<DESCRIPTION>
<P>There were no missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2009-10-22 18:06:08 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-22 18:06:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chen-1997">
<DESCRIPTION>
<P>No protocol available. An expected outcome measure was reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-22 18:06:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Datta-1987">
<DESCRIPTION>
<P>No protocol available. Expected outcome measurements are reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-22 18:06:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Harima-2001">
<DESCRIPTION>
<P>No protocol available. Expected outcome measures are reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-22 18:06:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sharma-1991">
<DESCRIPTION>
<P>No protocol available. Expected outcome measurements are reported. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-22 18:06:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vasanthan-2005">
<DESCRIPTION>
<P>No protocol available. Not all expected outcome measures are reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-22 18:06:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-der-Zee-2000">
<DESCRIPTION>
<P>The study protocol is available. All of the study's pre-specified outcome measures were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2009-10-22 18:06:08 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-22 18:06:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chen-1997">
<DESCRIPTION>
<P>The study is published in a Chinese Journal. The English language used for reporting the material &amp; method and result section is rather poor. Consequently important details may be missing.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-22 18:06:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Datta-1987">
<DESCRIPTION>
<P>11 patients were not included in the analysis due to 1) lost to follow-up or 2) incomplete treatment. It is not stated how many patients per treatment group are due to either reason. Consequently exclusions for reasons related to the interventions cannot be ruled out. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-18 14:59:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Harima-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-18 14:59:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sharma-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-22 18:06:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vasanthan-2005">
<DESCRIPTION>
<P>The study was terminated after including 110 patients instead of 258 patients originally planned due to 1) the results of a preliminary analysis showing no difference between both treatment arms and 2) the slow accrual rate. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-05 15:38:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-der-Zee-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2010-01-19 15:50:26 +0000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2010-01-19 15:50:26 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>RT + HT versus RT: all studies</NAME>
<DICH_OUTCOME CHI2="2.682907391779989" CI_END="0.7858312551157782" CI_START="0.3944036132215352" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5567177798490694" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="61" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.10467070184850621" LOG_CI_START="-0.40405911504171205" LOG_EFFECT_SIZE="-0.2543649084451091" METHOD="MH" MODIFIED="2009-07-30 22:17:44 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.44313988614541766" P_Q="1.0" P_Z="8.671199821304987E-4" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="135" TOTAL_2="132" WEIGHT="100.00000000000001" Z="3.3304298864867086">
<NAME>complete tumour response</NAME>
<GROUP_LABEL_1>RT+HT</GROUP_LABEL_1>
<GROUP_LABEL_2>RT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours RT + HT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours RT</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.301847747085431" CI_START="0.43207817600738774" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="16" LOG_CI_END="0.11456019585501065" LOG_CI_START="-0.3644376690716105" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2009-07-27 13:51:35 +0100" MODIFIED_BY="[Empty name]" ORDER="112" O_E="0.0" SE="0.2813657169355689" STUDY_ID="STD-Chen-1997" TOTAL_1="30" TOTAL_2="30" VAR="0.07916666666666666" WEIGHT="39.06634865424064"/>
<DICH_DATA CI_END="1.3364334113489078" CI_START="0.2809846224145781" EFFECT_SIZE="0.6127946127946128" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="0.12594732463077474" LOG_CI_START="-0.5513174472950498" LOG_EFFECT_SIZE="-0.21268506133213758" MODIFIED="2009-07-27 13:51:54 +0100" MODIFIED_BY="[Empty name]" ORDER="113" O_E="0.0" SE="0.3978286795439191" STUDY_ID="STD-Datta-1987" TOTAL_1="27" TOTAL_2="26" VAR="0.15826765826765826" WEIGHT="19.541279852410945"/>
<DICH_DATA CI_END="1.0657633046211594" CI_START="0.1501271429652706" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="0.02766076293539044" LOG_CI_START="-0.8235407802794655" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2009-07-27 13:51:39 +0100" MODIFIED_BY="[Empty name]" ORDER="114" O_E="0.0" SE="0.5" STUDY_ID="STD-Harima-2001" TOTAL_1="20" TOTAL_2="20" VAR="0.25" WEIGHT="12.371010407176204"/>
<DICH_DATA CI_END="0.7628192334845343" CI_START="0.2121660782390541" EFFECT_SIZE="0.40229885057471265" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="24" LOG_CI_END="-0.11757836532333768" LOG_CI_START="-0.6733240512133482" LOG_EFFECT_SIZE="-0.3954512082683429" MODIFIED="2009-07-27 13:52:10 +0100" MODIFIED_BY="[Empty name]" ORDER="115" O_E="0.0" SE="0.32644776687730453" STUDY_ID="STD-van-der-Zee-2000" TOTAL_1="58" TOTAL_2="56" VAR="0.10656814449917898" WEIGHT="29.02136108617222"/>
</DICH_OUTCOME>
<IPD_OUTCOME CHI2="9.862282048872185" CI_END="0.6264008048452496" CI_START="0.37270353314705823" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_SIZE="0.48317884176770964" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="59" I2="79.72071788163153" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-0.20314769293666132" LOG_CI_START="-0.4286364902110165" LOG_EFFECT_SIZE="-0.31589209157383896" MODIFIED="2010-01-19 15:49:05 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0072182766895966255" P_Q="1.0" P_Z="3.9850915443642175E-8" Q="0.0" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="133" TOTAL_2="131" WEIGHT="100.0" Z="5.491511152391671">
<NAME>local tumour recurrence_HR</NAME>
<GROUP_LABEL_1>RT+HT</GROUP_LABEL_1>
<GROUP_LABEL_2>HT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours RT+HT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours RT</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IPD_DATA CI_END="0.4839138049782534" CI_START="0.24946485454182316" EFFECT_SIZE="0.3474470995269354" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="-0.3152319882646776" LOG_CI_START="-0.6029906306164834" LOG_EFFECT_SIZE="-0.4591113094405805" MODIFIED="2009-07-30 22:32:16 +0100" MODIFIED_BY="[Empty name]" ORDER="33" O_E="-37.0" SE="0.1690308509457033" STUDY_ID="STD-Harima-2001" TOTAL_1="20" TOTAL_2="20" VAR="35.0" WEIGHT="61.40350877192982"/>
<IPD_DATA CI_END="1.3735434178865837" CI_START="0.48178805572910516" EFFECT_SIZE="0.8134843654078958" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="33" LOG_CI_END="0.13784239207877472" LOG_CI_START="-0.31714397103597436" LOG_EFFECT_SIZE="-0.08965078947859983" MODIFIED="2009-07-30 22:29:56 +0100" MODIFIED_BY="[Empty name]" ORDER="34" O_E="-2.89" SE="0.2672612419124244" STUDY_ID="STD-van-der-Zee-2000" TOTAL_1="58" TOTAL_2="56" VAR="14.0" WEIGHT="24.561403508771928"/>
<IPD_DATA CI_END="1.643292600187021" CI_START="0.41098362292614354" EFFECT_SIZE="0.8218067573052588" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="16" LOG_CI_END="0.21571489960832615" LOG_CI_START="-0.3861754837553525" LOG_EFFECT_SIZE="-0.08523029207351321" MODIFIED="2009-07-30 22:14:40 +0100" MODIFIED_BY="[Empty name]" ORDER="35" O_E="-1.57" SE="0.3535533905932738" STUDY_ID="STD-Vasanthan-2005" TOTAL_1="55" TOTAL_2="55" VAR="8.0" WEIGHT="14.035087719298245"/>
</IPD_OUTCOME>
<IPD_OUTCOME CHI2="5.630357917166867" CI_END="0.9923286281855491" CI_START="0.44948805893936505" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_SIZE="0.6678621631093391" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="54" I2="64.47827954414703" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-0.0033444792847922332" LOG_CI_START="-0.34728184120689437" LOG_EFFECT_SIZE="-0.17531316024584323" MODIFIED="2010-01-19 15:50:26 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.05989405251716051" P_Q="1.0" P_Z="0.04570779979087607" Q="0.0" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="133" TOTAL_2="131" WEIGHT="100.0" Z="1.9980817331242728">
<NAME>overall survival_HR</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours RT+HT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours RT</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IPD_SUBGROUP CHI2="5.630357917166867" CI_END="0.9923286281855491" CI_START="0.44948805893936505" DF="2" EFFECT_SIZE="0.6678621631093391" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="54" I2="64.47827954414703" ID="CMP-001.03.01" LOG_CI_END="-0.0033444792847922332" LOG_CI_START="-0.34728184120689437" LOG_EFFECT_SIZE="-0.17531316024584323" MODIFIED="2010-01-19 15:50:26 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.05989405251716051" P_Z="0.04570779979087607" STUDIES="3" TAU2="0.0" TOTAL_1="133" TOTAL_2="131" WEIGHT="100.0" Z="1.9980817331242728">
<NAME>overall survival (death within 3 years)</NAME>
<IPD_DATA CI_END="1.588010527593688" CI_START="0.22369271157366064" EFFECT_SIZE="0.596008708766031" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.20085337722249513" LOG_CI_START="-0.6503481659923608" LOG_EFFECT_SIZE="-0.22474739438493282" MODIFIED="2009-07-30 14:35:18 +0100" MODIFIED_BY="[Empty name]" ORDER="29" O_E="-2.07" SE="0.5" STUDY_ID="STD-Harima-2001" TOTAL_1="20" TOTAL_2="20" VAR="4.0" WEIGHT="16.3265306122449"/>
<IPD_DATA CI_END="0.8506174556957866" CI_START="0.3216770377073787" EFFECT_SIZE="0.5230909131025009" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="38" LOG_CI_END="-0.07026570928414852" LOG_CI_START="-0.4925799392624658" LOG_EFFECT_SIZE="-0.2814228242733071" MODIFIED="2009-07-30 14:42:58 +0100" MODIFIED_BY="[Empty name]" ORDER="28" O_E="-10.53" SE="0.2480694691784169" STUDY_ID="STD-van-der-Zee-2000" TOTAL_1="58" TOTAL_2="56" VAR="16.25" WEIGHT="66.3265306122449"/>
<IPD_DATA CI_END="4.895758602266081" CI_START="0.7311949822211816" EFFECT_SIZE="1.892023817012657" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="6" LOG_CI_END="0.6898199956799096" LOG_CI_START="-0.13596679758211547" LOG_EFFECT_SIZE="0.27692659904889705" MODIFIED="2009-07-30 14:49:58 +0100" MODIFIED_BY="[Empty name]" ORDER="27" O_E="2.71" SE="0.48507125007266594" STUDY_ID="STD-Vasanthan-2005" TOTAL_1="55" TOTAL_2="55" VAR="4.25" WEIGHT="17.346938775510203"/>
</IPD_SUBGROUP>
</IPD_OUTCOME>
<DICH_OUTCOME CHI2="3.26497412694115" CI_END="1.9784308997518214" CI_START="0.508020385470365" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0025383924411082" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.2963208863530953" LOG_CI_START="-0.29411886031517753" LOG_EFFECT_SIZE="0.0011010130189589012" METHOD="MH" MODIFIED="2009-10-28 10:40:26 +0000" MODIFIED_BY="Gail Quinn" NO="4" P_CHI2="0.7749299217465471" P_Q="0.9791056212598621" P_Z="0.9941678169026797" Q="6.859273552598047E-4" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="289" TOTAL_2="285" WEIGHT="200.0" Z="0.007309622618890215">
<NAME>toxicity (acute and late)</NAME>
<GROUP_LABEL_1>RT+HT</GROUP_LABEL_1>
<GROUP_LABEL_2>RT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours RT + HT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours RT</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.917837671710335" CI_END="3.309288651395307" CI_START="0.29572204140347846" DF="3" EFFECT_SIZE="0.989257092764052" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="0.519734649976653" LOG_CI_START="-0.529116304479099" LOG_EFFECT_SIZE="-0.004690827251223009" MODIFIED="2009-07-30 15:57:01 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5896339124124765" P_Z="0.9860127749052685" STUDIES="4" TAU2="0.0" TOTAL_1="156" TOTAL_2="154" WEIGHT="100.00000000000001" Z="0.01753128493812891">
<NAME>acute toxicity (&lt; 3 months)</NAME>
<DICH_DATA CI_END="69.5152908317231" CI_START="0.12946791838627933" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.84208034406391" LOG_CI_START="-0.8878378346245852" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="116" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Harima-2001" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="14.761425344628373"/>
<DICH_DATA CI_END="6.506556978823751" CI_START="0.15369111547852443" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8133512373159635" LOG_CI_START="-0.8133512373159634" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-30 15:57:01 +0100" MODIFIED_BY="[Empty name]" ORDER="34" O_E="0.0" SE="0.9555330859059092" STUDY_ID="STD-Sharma-1991" TOTAL_1="23" TOTAL_2="23" VAR="0.9130434782608696" WEIGHT="41.57299382772889"/>
<DICH_DATA CI_END="3.002608658675955" CI_START="0.0344968011105602" EFFECT_SIZE="0.3218390804597701" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4774987326476372" LOG_CI_START="-1.462221175200436" LOG_EFFECT_SIZE="-0.4923612212763993" MODIFIED="2009-07-30 15:20:38 +0100" MODIFIED_BY="[Empty name]" ORDER="118" O_E="0.0" SE="1.1394010756383572" STUDY_ID="STD-van-der-Zee-2000" TOTAL_1="58" TOTAL_2="56" VAR="1.2982348111658457" WEIGHT="29.238124382214114"/>
<DICH_DATA CI_END="72.0755724427273" CI_START="0.12486893541014299" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8577881003523775" LOG_CI_START="-0.9035455909130526" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="119" O_E="0.0" SE="1.6220210790715333" STUDY_ID="STD-Vasanthan-2005" TOTAL_1="55" TOTAL_2="55" VAR="2.630952380952381" WEIGHT="14.427456445428637"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.3550173139303738" CI_END="2.296051495533046" CI_START="0.443194400068265" DF="2" EFFECT_SIZE="1.008760211888143" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="0.3609816241331884" LOG_CI_START="-0.3534057357228041" LOG_EFFECT_SIZE="0.003787944205192171" MODIFIED="2009-07-30 15:24:57 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5078807677532591" P_Z="0.9834172447549818" STUDIES="3" TAU2="0.0" TOTAL_1="133" TOTAL_2="131" WEIGHT="100.0" Z="0.02078489803940665">
<NAME>late toxicity</NAME>
<DICH_DATA CI_END="97.99788802329087" CI_START="0.2551075385834674" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.991216716205615" LOG_CI_START="-0.5932767075335774" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="120" O_E="0.0" SE="1.5181442305531794" STUDY_ID="STD-Harima-2001" TOTAL_1="20" TOTAL_2="20" VAR="2.304761904761905" WEIGHT="7.640409932252496"/>
<DICH_DATA CI_END="2.575636800219706" CI_START="0.3619390526339713" EFFECT_SIZE="0.9655172413793104" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.41088462158322364" LOG_CI_START="-0.44136455469669733" LOG_EFFECT_SIZE="-0.015239966556736846" MODIFIED="2009-07-30 15:24:57 +0100" MODIFIED_BY="[Empty name]" ORDER="121" O_E="0.0" SE="0.5006153848482865" STUDY_ID="STD-van-der-Zee-2000" TOTAL_1="58" TOTAL_2="56" VAR="0.25061576354679804" WEIGHT="70.2642383679581"/>
<DICH_DATA CI_END="3.8353345302360315" CI_START="0.11588153287298582" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5838032505012337" LOG_CI_START="-0.9359857686125963" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="122" O_E="0.0" SE="0.8927315929044389" STUDY_ID="STD-Vasanthan-2005" TOTAL_1="55" TOTAL_2="55" VAR="0.7969696969696969" WEIGHT="22.095351699789404"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2010-01-28 13:19:45 +0000" MODIFIED_BY="Gail Quinn">
<FIGURE FILENAME="search flow 1.JPG" FILE_TYPE="JPG" ID="FIG-01" MODIFIED="2010-01-22 16:20:59 +0000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Search Flow</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2010-01-28 13:19:45 +0000" MODIFIED_BY="Gail Quinn" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAiMAAADnCAMAAAD7EqYIAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2010-01-28 13:19:45 +0000" MODIFIED_BY="Gail Quinn" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAASwAAAHOCAIAAACtk6OrAAAVkUlEQVR42u3dvY4cRRfG8ZEsIYIN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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2009-11-10 14:21:14 +0000" MODIFIED_BY="Gail Quinn" NO="4" REF_ID="CMP-001.01" SETTINGS="SHOW_ROB_TABLE:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 RT + HT versus RT: all studies, outcome: 1.1 complete tumour response.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAvoAAADACAMAAABCvzcFAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2010-01-19 15:54:09 +0000" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-001.02" SETTINGS="SHOW_ROB_TABLE:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 RT + HT versus RT: all studies, outcome: 1.2 local tumour recurrence_HR.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA4AAAACwCAMAAABpePBVAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2010-01-19 15:54:24 +0000" MODIFIED_BY="[Empty name]" NO="6" REF_ID="CMP-001.03" SETTINGS="SHOW_ROB_TABLE:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 RT + HT versus RT: all studies, outcome: 1.3 overall survival_HR.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA5AAAADgCAMAAABCWHlKAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD/gADAwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID///8AAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///9BjlLGAAAoaUlEQVR42u19C3Akx3nev+9d7APb+8DjDrgDQJFVdBQzll2SLieG
ZImSfOVjpEpRJRVjJhXmfKqKU5arJFlVsmSFihz5ZJ1EUrYlHss+PhymYkakQx6tBymF1FEig1gn
MXpFdwRwPBzei2lgscAusAA23fPs2Z3dnQV2F7PA/5G4mZ3u/rv/nv77757pb9pFAIFAOAVurAIE
Ag0SgUCgQSIQaJB2QGXUjFA97HzAVjQjvp/SE8Wyi/mA/Qz3B2QN66mphPOb4/anxLrqgPppUEEa
uKgr6N8rBV0OeahDgTQlsR05qSv3/Ne3jPWt1y7BrkrUGQbJNaynphLO/02M9RQ7q24aVDBf0NvE
3inorCHrRbcPJD9NUxr3+EZBCntoWGJdVSDA+ytKuwPuUqzPQ1iIm0Z4CPEfJ5RXYNHvoX57tbgK
n0pIhNV9mHoiIAs5QtxcCMuJdY0s19JBGiWlA9TtSyhOQqtHSk8H2PmRbiOaBFswGnCzULWu5JqK
dICCxdOqTlzBmSB1e8+zH0EfFANeQcEQzKp1QTUFI253+CAb5K1d87GhucEFgH//7fnb4Ynr0ZHr
R9j1rmklfOvq4tL2ZiYLR1jIJDc/6bsXfo0dCXSFtyJzK7Zy2YB/Ih9L14cik7xB/afY6yvbIHeK
4VV2OTy0FDtABrn8PJmavxkI+RF8xqjHp6YhNre8aURLwCl4V9f2TXNZta7gwevh4ckO6Lu6npJ1
ImQEDsHRIJlaOMXtbw66ZyOfEyYt0KfWBVEVLE1Go9dLB9Qg5e7rWqor13ON/frjGBTgCzA+xg4A
Y0klzrV+Fi8DJVZ3L4yBl13ZvBUuKL3gs3/QBQu2csqwtsXhhYkJ+fRYRk/5hg/64cUJ5kUPApRp
+8Zk+Ci8yjq3+5JfMeqR1fkGTEwaUcf6TsHG9B8ss/pT8TG4Oi7fBYcrqOk0upKMwMZz4XfIKowl
WNsaP2ZELdwdg40PK3UBWgt5gbWHgzyHjL0JA6vyL/Ynz6qT29pUQL2qh+hX+KH7al/0inJaD55M
SbZI9yIRxGrSlSzUXA/EHLL7aj8tsPPS0tCyqR71KuH/nv9A30wi9mZ/5Iq5ypLbjlcw9mbfi29l
55HJo1mm4CGpYKUgGe+dTah1oQaoLeTgDllhdDWdLPBHB0UJboYUlAixvN838xBTRa3AzGWbmfjY
bEHujHgu6copFUjFA/U66CpM53ndL/Uum+sxBZKkx/p3Q7ODkINpoZblcJfzFczBDJ+kpNfSWa7t
VF4LOCkqSI/ODWp1obkrHn5LW8vqCTmjzgqKkTw52xOYThcL0HP7uUDxgWcei03Ft+Qw9g8/qn+l
7GNRNYT93Xk5f+afX/7gO5aUOPUQl3rmz83Et7YLhx5cSm6oQsL5/Bk5dVf20fBSet2OpM6GVq/R
tSfPLkPoiVwfa4tiPQZXHj+blauB/1zvnjlSWJND1bp64JlHH1ryuxyvoKrTbaPbPgBVWzlsceXx
xDOGgtHZpa8roaqC4exjDy6tt1VBZ80hU9d7lpd7p1Kso3hv30twbGDl8t05q8iTA7kr/fqDl1/A
B+FU6rZNmzll/n7LtTyQAzq4sjKgi4+xKb0yUR1YXRnMHiAPGblZ2mKHGRhjMy6xHl/uXRHbxzqs
xJK389BYUq6rYwO5iXgHeEhVpyehwBSMpq7og67l3uxnhXh/CMNRpS6+pswcr332am6wvQq6HDlR
2v/zNwSiE+aQxuwEgTiIcKErQiDQQyIQCDRIBAINEoFAoEEiEB1tkKMhD3UHX5G5YAJq0MJGu9zU
E0zbiFkXNfiQZeWpmVCIa5JWS3ygrlS7fMtUwE2DqSo5Uh6Qokds1m1ZedIgualbgjT1VqRVz8z1
ZKmxfCXOJFz0u3X2nxrTF1d+FvsA/JSHXaQ+Q4QSybLA+sXRkJtGilBU4sboxwGC55WgRIC6Q6NN
4hjW0M3Hin26NbrRct0+0grdhJU6j8+M/rf45FPbuVXTEpUaK1aemC5FybVjk/Vj1kUBSChknbys
PGUIhXhSi7im0tQSnwvVk/poLmSjNiB9JZz3+9amz1rmWHjgWwCubHDdlI3d6ukunDwL+Q+eD1BS
LE+rlslcT5Ya8xWr0udDG+kfT+fX//xvkmtCzK3fev2M3KusbkJ4+bkNgKeyKbeurxzLusB6nL+d
7o+/2buRooe9LOJvwf8qzXz5aTlk5r94V+48+9RWc5Y/1dAtyHT7B6bb+ebrNqLodkjX7d8ouuW3
m6mb4CGL8DtAyabOBePkOJkv5mOdu9ozK/wwSk/4+K8N+AxI5AdabICY11+E0YA3RgVuYQS0CJQS
t3+memHy9AT79wTNazzIeMCjsB1TrEcPpmspEuHcRoUZyfzUEau3OQnKPR1r0mHqCUsiDzLP+jj/
qJVUrq9dvmUOwj7fcuaGKsEfA77YZVHk44n8wxcDMs/Tw/WUItTdJZkbxiVeNUyAT+eCQvG0t1uu
d6LVU0UfQf0g+ehFVpXHA4olD2V8sHIh7EucW1wTo5ILw/Jxg921APAFnXkIVDqMNKtEyetOSV3y
PWLFj+uh60DHWaqiwgB5daEEN3YpITcsRhJ3kvWmDu4E3WiFbpmquv3Khm7hGrr5ynVLNlU3wSC9
8KY/LxPB9Han8MUCrBjrEASBH/baHA8+BX/sT4jStiNzMbh99ltK9ajcwkmBW7gRm7uhhrfrfbII
6Sd7z2k8yM0XM1m5PHRu/WcztZazxSY5t1GOG+7avul1K2ak1DM7AzOzPdL14ej1J0DgQUZnSy/P
vasyhaKvXb7lBozxO12wDu1byEN+oc8n8vEYdLkfYLrC4PXIjUzPI5PD35kyDW434Y/gMLsPm+DT
uaAQOxNWano9mlkQ75uOhfhc99D847cC3P/z2W61lPNMDivp++E3TFFBaVObs+y8L/N9SGQ+aUFn
Wxic7SYLXZknpqLD7B51z0WNb6EcA4mT2zYhR4OL4Eofk/ITWn9yGZoNQ7eN4dm4rtuGhW7jgm79
NnRT2l+lbiVRt1taoptgkKtpmCsER839MueL+dnxw7JB6vywMdkOT7EUY0Hh4zTXxll9rENMMR0L
buHkeLX2Kg/kQxCHNQjqPEh6Kyj00BLccLJUqxNa5dxGhb2+MR1ZqmRGcvFh+ALcCF1eGB8HPq7U
eZDb0HtXaaNSqsCHs8G3lHmWCVgUchRCg5Bk/wVMfDxRrqxrASYyrLPNw/jbTBWVmh+dhevJ2eJc
KhPRuKCcrzguB1/PgN+yQoHeksulOefv2DhMqY3Wp5X0VTHmCshjF6mYlwt7guX/3ysnaewep3Pe
9DVWf+P8Xk7B+KTRK8II9+Olm5PDM78L4cvHhkJDbrk7XoREU43RrNtL43Bd123RQjdQdZutq9sK
101tf2W63TDCZAu6vd4S3cSVOtLQ2gL0rZtohwotDKaCKb7mVmAQKimIbwF6N8yxhYPILazNn1NE
Sne9uh5853Pycl5Tqhffl4GTv7CeNctJhZIJnL1y8T3veCmXWlBWC4vlJL92AVLfvrOWVBt8S5ln
KblO/sDIUfTPrtRCmsUo4+MJco2adctGLQgIzhya7lsPzB6a7i8YXFCLCi/TmFnHEgzmxPvAdVJL
qtwKLaZyZ/KEdwTFAGTYvfAZahifnolMKhLFe6ROeqIzfUXXlqwsvyb1XhuMU/77+AWFgtqcRcot
1S3usqlbnLZCN/G1RyI7PwSKv0uCfKLyxQKL98kOsoIflnDNH4VNZQIq/ytBCm7mfEJtnM8TyHko
M6JRqWZpEq8sRjKvJCp5kHcujPRfWK7VsYA0qnIbzZw9k/izFyIQVMSbKo8+N3I48z5LqZq+NviW
fhgBeAv8GCwf6CbuyQxk7kmY+HgVctNKPR0rL2FAnjMEoJtlcoseaOIrWqPoTd08yW+HzlxcZFn4
gE0c/icExJKqkvo8/F+ff/HwBb/PUmIknZoc1biqSV7vGnwF5t3Vp8D8mfKIt38hk1H8y03Nf0Ng
6Ka1t2botiToVpSq6+ZbaIlugkH66IuJWTYvZOVg9+4iv+U/hhE+13oOnlS+2xCC4WF40xjRUZLw
sho4qcRm3fYIazBZuBQ3xmlDw9DF2lnqCfn3HSO1H0VtJmeZgX8ZhtNUn3Tz8vhd0yvgqZUQht/D
hlGsfbCy/3y4Sqz/ALOwxLVIUb8hXoKAyzNmxbRV9WX9ErORqlL1J0AnV4vFbLILysxdxatsDPQq
t7mbhoSrZrkBuJSivw2vw8gMFZ86XGBtLQO/gl/CHDsbSimBARgeNOIkoViZaTwTXQM+snriBqVP
hUMQhUhydaZ4OjUuljSqPOa4169qPq3dqbLeJf7Lc2G4TbtHIRi5Q49z2p2KL3aB//jFERbO5hFh
SM3Ir4E+lfywFKenm2uQhm49alnt6xasolvEpFt6sJZuv94K3QSDXOt/Hw0fOgVfg9+GWOpffxN0
vhhTOiVrXMYP++GhZbp8KAenUnd8U7HQlZ6X4aXe+3TTUbmF0RT9z0qEibuXak0LfEE45CvjQfLy
rPaHc3d/r9YohnMbPyrz2KIKZ89S/AAc9sG1wRWp7xVjctAHuXuuHO6NVyZS9bXJt1z4lTuQu+3l
jPUcEsaVP5GPB1Amd3LgvVf6zrNqmzjcJxJBbwXoYTPyNH9oNDmwqnJBX+pbFTopXk/lGqeu9y1l
e6YvAvzJeN+S6sdfhkzCdTjnfqlfLGmPMg39+rx8aSwFyTHLZ5vXe+/jEu9V7tFSX9b4qM69nisr
wxS++6O3ZgfuZWOCf5GB8GH5q223xh9xZQ+dauoc0tBt0tAtXUu3Zw3dxqvoxiXmj1XXLRZkuh3j
ui3AsqHbStN0s8P2kKJd80H771iO//RqNNe3XmPsj2hSbxqpVtNVap4fpHTIkvNdetdzCcuE+Vix
rnw7cVoFO7p5FzpFNzsG6QZXrIFVCImVrcX+SMZK0CIaZDNBVkqZvmjGRkxPRmm0KXZMrFg2MG+U
WqVLbp/431Jd+See3rvvnaitiiYXq+rmi0pW6ZhuNsptR//2GiQCgUAgEAcP6CERBxrUYQaA9CsE
Ag0SgUDUN8iA8qAtHXDTd6fM1+q6flqPEFYerP6O+yxDq+5ByK6dN4JMMUzlrglfHG89wukGmQ7M
Kicrm6uR/7FkvrZ7WC5fASlXhX9cmK0q5gOz1kKFctfBl3IS3nuEww3ysrbxVmEr1KOuJNOvycxG
ojIK4wpfT+ZFqvw+wbNR9+lRgwJ5OkD5OqWgvEWtnLpb2Y9QwfCCvg+hpPAUFT6jW6H3JfweZWOc
MHycxiHiVpYo8qDzfm9cZVn6Ff6jXm4vTUGK+lRem77/YdAHeT/1BIpw/8Iw3nuEww3ykMEd9o5H
FYbnIY07Je8FqDEKNzW+3mtzxn57Kji38IzALXxquncmDcWZHgA1dV7Zj1DBh2BO24eQKDxFhc+o
7kG4/mZG5nL5NuCr8Luwwce3KvPv97sX1GUZnNdoKncQNvh/Kq9tWcvvwhxE50ovzf4+y/NDeO8R
DjfIfFI/nT+6otCK89qqeGUvwC64Eb4AXTpfbyxh8PtUlHMLx5IhWIM4dDEnq/ARtf0IZfw1+LR9
CFWeoonPONmvnLq2pNnU16Q5YQX49QUtlrG/o1puzuBch1dUXpue39sSLF7vydI5WGH5IhDOg/k9
pLHYVHLJBEgwLRWkyUzPQumu1xZSCl9PDjL4fUpMlVsokPSkNBQCrgUXlBQ+4rCxB5+xRZ+x6aN5
D0I1/8jk4OTRNwcnB1bLN4okJtqaWu7jFyKBYz9QeW3Cnn9AlhchFV3CZbUItXl3zHvIsp2cU5zL
6EoEof9CKCHy9cr4fQK3UFtWmNjMRBc3Ezof0bQHXwokjden8hQt+YweWEteTa7Z2K9XLncMoouv
a7w2MT+aGR5gg2AJdw9BOBKeii/M0ULIC99/51Jqg52B/t2tB555lu8FuLqRg20PzT4+8Wl140Zj
vz0lZuATqf/3+fD2nZf/8RtZ9Zp0fy65+EV2+pycWtyhD37vB2c96j6EYb7pY/eW27QHoZp/mObj
f/p7L0Ayr+4HqQYJ20byMa9cbnaWWcqx+aa6v6SYX+ATr/zFhtf9+Y3uTbz5CNa8HbYLqKWHfMl3
28RgGY/lXmUvQN8AJyyKfL0yfh/k+mVu4S9Td+hfoEkeBr88P1X4iOp+hAr+Dnq0fQhVnqLKZ9T3
a9TK6ee8TLm8nJ9Yu9zfAUiHNF6lmF/snrfmevtZnkFsiwjHzyH3AFLP2Y82X2g0tPCzW2tEePBj
8wm8+QjnzSH3fnF5PL/e/FpOuSI1FwgEuii2RQQaJAKBBtnwHBKBQKBBIhBokFgFCAQaJAKBQINE
INAgEQiETYhrQ5UnwObnwFWfClNQ14aLhxY+RKZgbzl4WYFsJCA2xNuQaoQpZ/KLzl1Uh2VVlhdW
LxdpRd1b5KNtXiMv6K8Wai4/Ba0+yB6s6efkvViHGqQVSI3mwv7MB2jd23Zqs8WVFchWo6sv3oZU
I0w9I7Cr+qB2CmuUi5IW2KNFPpr+pGaoufxCJILrMXZkkGofT+TbTAWCk94JEus72NL6Jk2K03iR
yc6iNNtGhMKSHWnbmtonFhGMojarEnbYtDz1ktKmtaXWGaTu8Ij2kwKx4XhaqkFrRjutLDIlTbE9
i8Ja1EWLV5w0Wvuk8clGa+5Utk5Sp63U8Vp1FqSy6yNWnWA7C6p2By22g11JbVuFCHWhsK5lmnYr
52f1at/oui0tSZ/6IhoySL3aaJPHDQ53ZW163tQ08yfiKVU/MWS/x2pv7Wu9uv5JiPYi1skGaRqy
1gugDjWR9jtIYh1lVwWhDaane/q4pJaD7IAe1UlwN+oK0R7bkTH/lAmxZbYOqnPrGqCOKmpnesiq
wwsjgCoDNaIM1whtdQ9oNwdzuZol3oZUNQolra8Moj0EN7JSzkmL8zFpZoRqqus1YDLVtjWR/QHk
QyKaO2KoPVJw3MAK+ZCIfWGRbU2GHhKBOPC+3jlzSASik5EVf3TYew8csiIQaJAIBAINEoFwOOzN
IStmvuq+OBYxrWiSu3oF1SC7UGTf2Rdvgw9ZXaoFSdF+EaoyHK1SVxS2jXxIk0r1+ZDWGuEeR80x
yAoQsG4AljRJupvW0jC7UKTo2RZfN34NqZWMygaKUIXhWJ3ORcke8CErVarHh6yiEfIhGzBIrV41
LiSIhAKRIyl07eV9Y/P7P1LdTdvy5bbF25RqwXuilpHt0aOrMByrq0EsYrcctVUidqqyRUsaLa96
6kchHWCQ5q5NJw8oNlrOkWzMvzSxUdgfZrVi8GYx5CK7KUJVhmMVGbRqMWiLyai7rlXa2u5aRLYj
TK+uQSrfByAWehBaqR8lbesKG5JYtsjTTkOxsdKyvJeyUYSGSL2iYG18Z5GTeRoglr7FfEhi/cWl
8u7EKlSrWuJcQoKz55DU1uhAW+BfO037QSqnP3VT2P8UArHT6ROT5J319LYHh+3hQxI7dVj/IQBi
p0NW2zelsoW0ykE6sXfdK6ZX7cno3s0b0APuHm7T4IJY+zta4SQpKQ+kjhiwNuyrafOl7m7U0NDX
Lto1MqlNgrVFkcXHq/bgKn9Gw+cD5jGcckF/yirULrH4XieIL6ya8B6SQmPzj0aztP0esnosanoK
3WARyhKXVWCtYghZqeek+XZoysd4GWxuEKZQo1e3qo62ONFG1rLi/pCIfQDkQ7ZjyIpAtGpqgANX
9JAIBHpIBAKBBolAoEEiEAg0SARi/8JbPr2t+9S6sR0jrXl9O5l2219crr0Ua+jL33b5kEDqSdDf
1jX46fHyWqz6ylPghraWD2na47H6/pBV3p1SC7ZkJ/Ih5beasT0wyCbcPAsO5K5vQKMLX2yRgaoU
fhdSDQmazexkeU+dejN44bSszlvBhzQ0qL0/pFqesjqkVmmRD9mAQRJqudJE5EdSYUlIOW+S1Oxi
d2HnVDg02Z1a2dwOpZJK69xJ46vJh6zYdLHFW9DZ10Bb4e5wUJvXTPA05A9stqhGPGSVzZGJ3MEJ
XbItRtKuWXCNOrydrtaju93SvNx+ya7avmVOpEY/R9tFNrTZ71InOkOyE5eRbX3XV9sgTeQeC+aR
uXMmtZVrOwuO6N11o1O4Ov6vvtQmKUobYQ+2hw9JzPPFRjs1HKfuzCCJOhGhpptgjx/ZRKfdVodq
r6CkxdpQstN6aw8fkuq075p+r5xlrbWjzp45xvbMIMXa1zvpavxIi+sHnA5Hyc7rQdgOcmc737Vn
hEjsDw1omya6+w1u88hE+OofresLqa3bsifTdtp+qbvpjoTtIB3Jh7SVHbXWCMeru55DKmMMY18/
sfPVm13FSMRyx8i27wq4w3zrxLch1Wp3xB342Ab2t2z5/pAV+VTZH7LaBcD9IRsHsj0QzZj02h0p
IB+ykSErAtGU0atTxtidPodEIOxOeqsH7TBdK3Ex4vdGEhIOWRGIvUaxZ2N9gZ8kXX7/C293+pDV
E8Jbhti3WHzY5Z7Krsnn+bWVpScD4ZxpowEoOMwAhCHraMhD3cFX9K5DGe9fDOgREu+GssC4n6Wi
NFKEIuWAGP04wEfOq/ED1B0a5XF98TaoEmRlSvndNHARUiznQKopUt/NpKYDbvrulJbHHiHAsi52
yTU62uWmJ4raPesqsmqPAYSaWsmjITcNy3lA7Aj1J4Aqd1i++RSKJ9y8JIoP8rDLo3ow6OVUz7pG
QQq63eFZMGK0A6mP+9NXZzImA525mvOpajl+yBqY/dmtZDy9qc+/y7eRqDiVegKroemR0sRgjowf
yrMrxy9LWzNHFIXzYf/0pd/sW2dxS+96LtHq2s/NsDIFN1a9ufTmieyf/avLqa3dS50ZmuVSizku
Vc1jT5DO8oKErw+Xrh7Kd00NuSYGVtll9cw7ObhZdDV1e/quqaNudl/Z2Yu/OTJ/+z+u8xngeN+6
evPlkhxWXE9kkl2IT/QX9MRqOWUxwb6rA1oraR/9Sgql/tkFSC4qv8qPvb7AGwnHD1lL+efXC6Ft
oMyLs78C9G55Xvui7NTD21J6w51np+mtTNgbzxeAp/v6dDq/nYfp+/0lbzbB79XUqqv0cGBdltc9
1//Zx0NbwOKS0cfWW6zIVNcqK9NmyZdcim69MXk+SGNNMMhPh1WpKRrZVvPYE0zJBdleo394/8gy
rNKPsjpnl/vn2Flge/EvF0OxSHOreHVJzePvcuCZ5HUp/emaTH3gN7/ES8IaC/elD6+xC95s2jBI
rZwA8xCduT+4XVpjrSSwDYW21J/08B0fWcku5iGfZJ1CsvK46pv6C39EHrw6eMjqhTf9eTFsKzx/
m7xQ8sHr4eHJ0jY/XX6eTM3frEb4EMzBMZCYLcMm5GhwEVzpY9ItE+roHC5rksah1fYIn5xTjscn
0tx1+MbSuSZI/cysWjfj0TXe/PfsPh1alftMSCTgdXg7P3Bbgev8bBtS6dTi+kRTMzTymEmdpkH+
hHJoIe7TTY4HK09Ibo/wf++BrPu09hxTLSf3Sbx5vB0y/LDdnoFqd/CuiSeZK+TesPrf4uzVwOnu
GccNWQUPWeheW90kP3yE92LsrwDLJ7/qL/FfL66x3jIin279g+vs6mJJ6el+shaGt/70iQeX8iHP
YDA2eeWN6Pi/vXf2wWKU258ED6mGGfrk/blWd0Q/OqOU6fXHppNs1J15bDq12YSZlCo18+g8E7d5
prBXHnLTw7OWlFvzf/khH5LrWD6LjqfzP3lw9jM/bF6GRh6FtU+MTp7bZA7y6OQZ9YYqGS9yg03l
V/mFnpn1xIVzapWr5eTzoNzjD9HFUmLlN36H5kPt8JBdkuda3lbMfP/UuTUHe0jf/NE0zNxqXEi8
HZQx94LeW0L3la1l9Sprpuzv2f7xfDIF67ML4/AkZMmn8qG1hNydnwT9xU+C9ZRtQmICNpTDdDOl
XpWl7jVSSr2WnSdZtV/9yvf+6U1faUl+AO8f49pfyqwYDwLk+ym3g1xYvvDNLd+4XkdG2Vb6sx9k
v7L9H8ifTLWljjKujfXh/qRcwlp/98Rv+m424zgPKS4MSGTnh6DIS6s8lZEk9Y6k+KlLPr0K03nh
rkjgK5B1bUUsjz3iW1jIyHrG4CZ9UN/eB1XK4ebmSi054REcvxGT0MMPMv4PSEX5Ho4E335hoZnN
qxdGJcG6mO29H/zCyAqkUUjLI9pxqq/AWTSXk/fyhe1zGR9vJYVXve2qJt9SIXNDMK2OTpOVR9fg
SOmbrgUnPmUVPSR9MTELp9ilvPLk6cglCMh+7sswNMJmicwu2d9NQ3qKUxCF0+5UfLEL/McvjrB4
AKth+PUZ+R5+KvlhKU5P89MoBNp0K9wXb2Al9dHUJcg1TarXzZTrcsDdCsLIJTYu+RIMj7Bz/j4J
LqXlul17g00kTzYxqz+H96h5BGHoLTAAsA5vGMEBGHkvM1AWzHkdQJSaH1Tfh6nlZD8Cx9NxeB78
7hmy2M4aTEhrmzc+3iP2EtrRPfDThRxNgDMhzCHXk49J3eSrj3R7hp/+Kz6HTD7rWfHk6MNbn3tm
bTrugm7Pl7e6+zOeLA/k6caWBgoPPDHp7V0CMvAfPclPPwKJd/4M4M/kB37nyWuf8Ma/yuekKZps
+VMdeX6SLP7N+h+NQsJ/7Wll3NwUqd//27+elt8AwJ7NIZWsV9PXvkFefuRz31ibvud1Pquce+TR
6cPLHsiHzgCbvzdxDvm5b0wuDSzxPIqp/BTPY1F9JqCU5O6LS4defkSpD6WOvkgHr50pJPlIQi0n
u95d+IU3/QjkQl/a6Flqc/2tfWvb2/+eX5gdf3rTVTx/RqhWh80hd7V0Tuo5+1F7wz3vglN7JETD
qPUy8eIdmztN2iJIl+7aKMneMeUP/LK/okT7aju6eN6e4/NFJWzH+8cgk4tVW02Q1vI4NJXZk/ZP
iuslf/ANK6eA+0MiEE7qXZAPiUAg0CARCDRIBAKBBolAoEEiEAg0SARiH0HcH1I5VH5/u96T4VY/
Od7FjlY2hIPxaVMEwkEGSRzaKFvzMXJR7VaKRyB2O2SVv3wif0Lb9A0U9TIYARSsY3YQ0C8inOoh
xTaqbAVp2hNX/FGxaSRtnXttcMfWHfhfAg7dzhCBHtJqNGe6REXDI3VidwAIbrONcLaHrJy+Vf6g
lXbauq1eWjm0tL8HHAKx1wZp3gOS1PKGLRyy6uVopdVQNEqE44esFa6Qlu0hWdVjNnVIKe9mZuyg
2GxDFHJBIJznIfW9zIlpD0hxVFo2QpVjdmaDxm0LEY4C8iERBxrIh0QgEGiQCAQaJAKBQINEINAg
EQgEGiQCsZ8gvoekZbzAhp8Iq6vMTZe0d5pqBJ1+aIqiXtIil0VRFuoQK7mG0Mq3iVSkVulyhQJW
K42wWI86lpSG2P8GuWsQKxM1L0YnFqt6yvgkVswRq9/CKldSM4pJLhHjVZZGT0X1HgbtEbHXQ9Zy
RqRIeaRUIUUKjEgxmhFfMxKiJVOZlDVtjZSbtUleDdNvqMughnRip19BIPbSQ1YyIo1T/j+UMSIN
v0I0XmH5SnRtNEvFJeukYvRZYQxKdsRwWlDTnmlNi5LFc1lGfhWlUctg8CPRQSL2yiCpvcGoSCCs
bK3EcpBHzMcyezVGn8bMrTI7UtUS9bkgaWyKa1EaUyRlMS9Fn4nYE4MkWuOm9W2Ugj1TbmTiaVht
g26JNC+WmX5JLO0YgWjvQx1SvxET+23dojnTnUzWzCNLUjfKzgSbBrP4bQ+EEwwSar79sJ5dUYOb
JQz5qrw1IDXM1eLNieXIcueusn4qfNmBcJBBmhiR+kRLOVU5kmYeofDL/MkNG3RDNQp/1KLnYBiE
iZIpGqkmuOpbiVpyqxtbeYGV5GibiDZhR3zIOs6jOb7FrpRGc6Po/RDNbqxtGLLWmm8RJ6nY4It7
tEXEvvOQCAR6yNYAF5cjEGiQCAQCDRKBQINEIBB2UX1/SPOkt7F3cRWrzWjF2zxKTNlWYyVacCQb
4T8CkqcQnWqQtd7P7bJZ11oO2gCXUQ+zlUaJhhaJ6PQhKxU4jir5sYwaCVV2i6zcJ1ITUsaoVKiT
Vc29rSsLEAhHesgyVyMS7MuokVBjt8gyXpTIrBT5kyIrsdbYtY6Z1UyjrZhDw0R0skHW8VRmqiIx
7xZps+1bMhuJff9mj/+Ia+QQ+8IgVbdjfxsaanla+Zs2a2hJmhYJgXC8QZJGHQwxD1GrWgWxYdaN
7aBK0fQQB2HIapclT2iFAdGaHrD8U5Mij3IHXpPYnm0iEB1qkGb6oPE1i2oMSDCTJk30RVMigVEp
y1W/n2PxVpHq31AtK8wO+Y8IRIeg89geO+E/IhAd0jw6b+lcg9+4QXtEdBI6cC0raWFsBAINEoFA
oEEiEGiQCAQCDRKBQINEIBBokAgEGiQCgUCDRCDQIBEIBBokAoEGiUAg0CARCDRIBAKBBolAINAg
EQg0SAQCgQaJQKBBIhAINEhEp4A2Od5u0+xdISgaJAKBHhKBQKBBIhAdAxd+JhHh8DnkAYBhhV6s
DMTeN8PahrsDp2E7DXVEIXDIikDgHBKBQKBBIhAdA3yog0A4CPhQB7F3EHYPtXwAYoRT+4+AxDT1
E9nfqpvsQLtaidS9i8vioEEi9s4ejf10ae1wanvnXTEmsWc0DUq1D1I/5wrBOIdEOMQ0d9y0d+H7
7BpZ8/OvFooeEuEAtORJho1hZkufoNTMn+AcErGvnahlm2/i/tltyh+HrAj0ug7KHw0SsU8dZGfm
jwaJ2Kf2SDsyf1wYgNhDMzMmWjXeQ7Igan8MaMi09e7Q5suUnYxB6+Rv/R4SDRKBcBBwyIpAoEEi
EAg0SAQCDRKBQNgFrtRBdAAafMopR++LZtQ3D2ZGCSVll5smHz0k4qCAMDQWveRb4QewSGhxuany
0SARBwOJAPV0g7cIoz4oBmmgqDgr9kdjHiBu6k8Yca/Nlvu0FspHg0QcQKyEybdXIJCE92xAd4A8
320EPb0Ay98hkRXjynCf4+SjQSL2yySScldVlODORfAfh40CrE9ArGBEeFsCfGfJG0U9Ol2PCalB
Ts8v0xbIbyI8IbzZCMejQEK8oUp/6YG10PRHSu+YAekheMRVggK7zv4KD7HD1NrF/Joa/ZA/J5sT
D4dQiF1RpLDTkHa5afLRQyIOJHrdwTyf6ZV+wq0HpEX5qqSG+tYzP9f9Hw3+S+fJR4NE7Cts+cf+
ih38Sz6AwzfApcP84Yo0qBnMiwnm0jRkvyc+/SQtlo8GiTiA6F5O/Qk7vADjAMtr9OQywN+PpTya
idxHx4V5XW5l1GnybQDZHgiEgyB4SEqtHkJRLbCWlMa4mFR9u0PrSK2ZGbWTOa0MpTspMQLRJnhN
w+yqbM1mf8BApZ3uTGpDyXAEgOhQDym6Sv1A1aUKVLtMNQ+l/lKdjZYEaFls1U3pvlCNqFwyS9VP
TRKpOTduY1QsaHmBTEJ0X2yIEouCfhLhXA8pOiDVfVFCZHdE9N9VPiWthGvfWhBim8LB+ByDJlKQ
aj41BasHYlVQYi6QOZG5cOYQSvb+00kIRH0PWXu8R6xCiemE1BRE6uRErCOKMWh1AdZfkScVERCI
DvGQugur+eFl2qSmTaHm0xnrshALz0YbyAkf7CA6yCBJ/Yc8zfssNLHlj+vnpn5mrJEI6CsRnTJk
pfX8R9lbB1rd69Dyy9Suk6TVy0KqelPr1xrUuijoJBHO95Dq+FAbJup7e5mGjUYk2Tb40fhVLRxM
UcqlVmRAystCy/IXS1iWk55hReHEoqCTRDgMTV+pY/3B27Y1fG27QbQ0REfi/wOCRFXEVTL4+wAA
AABJRU5ErkJggg==
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-07" MODIFIED="2009-11-10 14:21:03 +0000" MODIFIED_BY="Gail Quinn" NO="7" REF_ID="CMP-001.04" SETTINGS="SHOW_ROB_TABLE:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 RT + HT versus RT: all studies, outcome: 1.7 toxicity (acute and late).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAvoAAAGACAMAAADrkDbdAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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=
</FILE>
</FIGURE>
<FIGURE FILENAME="abbriviations.PNG" FILE_TYPE="PNG" ID="FIG-08" MODIFIED="2009-11-10 14:18:36 +0000" MODIFIED_BY="Gail Quinn" NO="8" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Abbreviations</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAhUAAAIRCAIAAAByF9g/AAAhU0lEQVR42u3dDY7jsI5o4dr/qmZn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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2015-11-26 13:10:34 +0000" MODIFIED_BY="[Empty name]">
<FEEDBACK_ITEM ID="FBK-01" MODIFIED="2015-11-26 13:10:34 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2015-11-26 13:06:40 +0000" MODIFIED_BY="[Empty name]">Sergey Roussakow</TITLE>
<DATE_SUBMITTED>
<DATE DAY="5" MONTH="10" YEAR="2015"/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2015-11-26 13:10:34 +0000" MODIFIED_BY="[Empty name]">
<P>The review is heavily biased in result of (1) inadequate bias risk assessment, (2) misleading statements and (3) concealment of negative information.</P>
<P>1) The statement &#8220;EBRT doses between 45 to 50 Gy and cumulative doses between 70 to 90 Gy to &#8217;Point A&#8217; are considered standard&#8221; is incorrect and misleading.</P>
<P>At first, correctly it should be &#8220;EBRT doses between 45 to 50 Gy to &#8217;Point A&#8217; and cumulative doses between 70 to 90 Gy are considered standard&#8221;. This is not correct statement because with 45-50 Gy dose to &#8216;Point A&#8217;, it&#8217;s impossible to reach cumulative dose 70-90 Gy (dose to parametrium never exceeds 25 Gy, usually it is much less). All the radiotherapy (RT) guidelines recommend cumulative dose &gt;80-90 Gy [1] with &gt;70 Gy to &#8216;Point A&#8217; (usually 75-85 Gy [2]). Perez et al. [3] showed that dose &#8804;70&#8201;Gy to tumor mass significantly reduces the efficacy and is considered inadequate. 40-50 Gy to &#8216;Point A&#8217; is undoubtedly inadequate dose.</P>
<P>2) This misleading statement is to conceal the critical defect of the main positive van der Zee[4] and Harima [5] trials. Both trials used inadequate comparator &#8211; low-dose RT (&#8804;60 Gy to &#8216;Point A&#8217;; though 82.2&#8201;Gy cumulative was used in Harima trial, dose to &#8216;Point A&#8217; was only 60.6&#8201;Gy (30.6&#8201;Gy EBRT + 30&#8201;Gy of brachytherapy), while 21.6&#8201;Gy dose was applied to parametria with central shielding), though the best or standard treatment should be used as a control in clinical trials.</P>
<P>3) As a result, long-term overall survival in van der Zee trial was twice worse than in RT-trials with adequate RT dose (23% vs &#8776;45%) and the best OS in the termoradiotherapy (TRT) arm (43%) was also lower or equal to that of standard RT studies (everything is described in details here [6]).</P>
<P>Therefore, both trials have incorrect design and are clinically insignificant because the same or better result could be received with standard RT with lower costs and labor and lower toxicity.</P>
<P>4) In Harima trial, pre-selection of older patients is obvious (selection bias): the median age was near 65 years and these were previously untreated patients, while the average age of the first diagnosis in Japan is 54.6 years [7]. It&#8217;s impossible to obtain 10-year older sample of first time diagnosed patients randomly (the better local control after TRT in older patients is well known fact).</P>
<P>5) Van der Zee trial also has incorrect design. In fact, it combined two studies based on Amsterdam Medical Center (AMC) and University Hospital Rotterdam (UHR): whereas AMC trial was monocentral, UHR collected patients also from 9 other RT centers. As a result, two groups had different RT-HT sequencing: if in AMC HT followed after RT in 1 hour, in UHR the usual delay was 3-4 hours because of logistics. As interval of RT thermal modification doesn&#8217;t exceed 3 hrs, it was a concomitant instead of the combined treatment in UHR arm. Additionally, the groups used different HT-equipment: BSD2000 system in UHR, 4-waveguide applicator system in AMC and TEM applicator in Utrecht. The statement &#8220;Van der Zee et al used three different radiative EMsystems with similar energy depositions in pelvis-sized phantoms&#8221; is misleading: according to Seegenschmiedt [8], their thermal efficiency differs 2-3 times in clinical setting. These two studies with quite different protocols and equipment should be analyzed separately, but there are no separate data for AMC and UHR; even the number of patients in these two arms is unknown (incorrect analysis and incomplete data presentation).</P>
<P>6) Safety reporting in van der Zee trial seems to be incomplete and biased: synthesis of data on side effects and refusal of treatment gives much higher toxicity rate than it is reported [6] (concealment of negative information).</P>
<P>7) Therefore, the both trials should be excluded in view of incorrect design (inadequate comparator), selection bias (Harima), concealment of negative information, incorrect analysis and incomplete data presentation (van der Zee).</P>
<P>8) Vasanthan [9] and Chen [10] trials were negative.</P>
<P>9) Both remaining Indian trials (Datta [11], Sharma [12]) are old enough and of low quality.</P>
<P>10) Datta trial seems to be rather controlled than randomized.</P>
<P>11) The information provided concerning Sharma trial is incomplete: there were 4-time more distant metastases in HT arm (4 vs. 1 in RT control) &#8211; this information is concealed.</P>
<P>12) After exclusion of Harima and van der Zee trials, two negative trials vs. two positive trials remain. Vasanthan negative trial of highest evidence level (multicenter international phase III RCT) shown no local effect of HT with negative effect to survival (statistically significant at IIB stage patients). Chen negative trial showed no local effect and no effect to survival. Both positive trials are of low reliability and show the higher rate of complete remission without effect to survival, but with progress of metastases (Sharma). Therefore, the negative impact of HT outweighs.</P>
<P>13) With respect to the above, the conclusion &#8220;However, available data do suggest that the addition of hyperthermia improves local tumour control and overall survival in patients with locally advanced cervix carcinoma without affecting treatment related grade 3 to 4 acute or late toxicity&#8221; seems to be inadequate.</P>
<P>=====</P>
<P>[1] Colombo N, Carinelli S, Colombo A, Marini C, Rollo D, Sessa C, and on behalf of the ESMO Guidelines Working Group. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2012) 23 (suppl 7): vii27-vii32. doi: 10.1093/annonc/mds268 [2] NCCN Cervical Cancer Guidelines. Ver. I.2015. <A HREF="https://www.nccn.org/store/login/login.aspx?ReturnURL=http://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf">https://www.nccn.org/store/login/login.aspx?ReturnURL=http://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf</A>
</P>
<P>[3] Perez CA, Grigsby PW, Chao KSC, Mutch DG, Lockett MA. Tumor size, irradiation dose, and long-term outcome of carcinoma of uterine cervix. Int J Rad Oncol Biol Phys. 1998;41(2):307&#8211;17 [4] Van der Zee J, Gonzalez-Gonzales D, Van RGC, Van DJDP, Van PWLJ, Hart AAM. Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: A prospective, randomised, multicentre trial. Lancet 2000;355(9210):1119-25.</P>
<P>[5] Harima Y, Nagata K, Harima K, Ostapenko VV, Tanaka Y, Sawada S. A randomized clinical trial of radiation therapy versus thermoradiotherapy in stage IIIB cervical carcinoma. International Journal of Hyperthermia the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 2001;17(2):97-105.</P>
<P>[6] Roussakow S. Critical Analysis of Electromagnetic Hyperthermia Randomized Trials: Dubious Effect and Multiple Biases. Conference Papers in Medicine, 2013, Article ID 412186, 31p.</P>
<P>[7] Ioka A, Tsukuma H, Ajiki W, Oshima A. Influence of age on cervical cancer survival in Japan. Jap J Clin Oncol. 2005; 35(8):464&#8211;9.</P>
<P>[8] Seegenschmiedt MH, Fessenden P, Vernon CC, eds. Thermoradiotherapy and Thermochemotherapy. Vol 2: Clinical Applications. Berlin, Sprinder, 1996. - 420 p.</P>
<P>[9] Vasanthan A, Mitsumori M, Park JH, Zhi Fan Z, Yu Bin Z, Oliynychenko P, et al. Regional hyperthermia combined with radiotherapy for uterine cervical cancers: A multi-institutional prospective randomized trial of the international atomic energy agency. International Journal of Radiation Oncology, Biology, Physics 2005;61(1):145-53.</P>
<P>[10] Chen HW, Fan JJ, Luo W. A randomized trial of hyperthermo-radiochemotherapy for uterine cervix cancer. Chinese Journal of Clinical Oncology 1997;24(4):249-51.</P>
<P>[11] Datta NR, Bose AK, Kapoor HK. Thermoradiotherapy in the management of Carcinoma Cervix (Stage IIIB): A controlled Clinical Study. Indian Medical Gazette 1987;121:68-71.</P>
<P>[12] Sharma S, Singhal S, Sandhu AP, Ghoshal S, Gupta BD, Yadav NS. Local thermo-radiotherapy in carcinoma cervix: improved local control versus increased incidence of distant metastasis. Asia Oceania Journal of Obstetrics and</P>
<P>I agree with the conflict of interest statement below:</P>
<P>I certify that I have no affiliations with or involvement in any organization or entity with a financial interest in the subject matter of my feedback.</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2015-11-26 13:08:39 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>1) No single golden rule exists regarding the optimum radiation dose delivery in cervix carcinomas (Viswanathan A.N. in Perez and Brady&#8217;s Principles and practice of radiation oncology). However, several principles should be respected when treating these patients such as the awareness of an obvious dose-effect relationship and critical role of brachytherapy (BCT) . </I>
</P>
<P>
<I>When discussing adequate radiation doses one should take into account the techniques applied (e.g. LDR versus HDR BCT; EBRT with our without central shielding and the type of central shielding used, reporting the dose delivered to point A, which may vary between 50 to 80% of the dose delivered. Last but not least the loading pattern used in BCT and the total activity applied are important issues when trying to compare treatments. In fact, none of these issues is addressed systematically in clinical trials. For sure, treatments with a similar dose to point A can actually deliver largely different dose (-volumes) to both tumour and organs at risk. Taking these inevitable shortcomings we accepted the surrogate endpoint for reporting radiation doses to cervical carcinomas generally applied in literature, i.e. the dose to point A. </I>
</P>
<P>
<I>We do agree that the current statement about dose levels to be considered standard is not extensively covering the issue; however it is not incorrect and not misleading. The dose effects reported in literature do apply to the <B>cumulative dose to point A</B>, and more recently the D90 delivered to the high risk CTV. The latter is, however, not applicable to the current Cochrane Analysis taken its time perspective. The dose delivered with EBRT is typically covering the primary tumour (surrogate dose to point A), the parametrium and draining lymphatics. Additional doses to the (residual) macroscopic tumour are applied by means of BCT. </I>
</P>
<P>
<I>2) A dose to point A of 17 Gy HDR in 2 fractions (van der Zee et al.) or 30 Gy HDR in 4 fractions (Harima et al.) would correspond to an EQD2 dose of 26.2 and 42.9 Gy respectively (a/b =10). Taking the additional EBRT doses of 46-50.4 Gy and 30.6 Gy, both treatment schedules can thus be considered adequate. In case of the Dutch trial (van der Zee et al) several patients in both treatment arms could not be treated with BCT for technical reasons which are well known in clinical practice.</I>
</P>
<P>
<I>3) The criticism of the van der Zee trial concerning the poor results in the standard treatment arm as compared to results reported in literature are discussed by the authors. </I>
</P>
<P>
<I>Of importance, the patient population had several poor prognostic characteristics such as a tumour diameter more than 6 cm in 77% of patients, and clinically suspect lymph nodes in 70% of patients who had an abdominal CT scan. Although they are not included in the FIGO-stage (except tumour volume in stage IB) the detrimental effect on treatment outcome is well known for both tumour characteristics and may largely explain the poor outcome with radiation therapy only as compared to published results in comparable FIGO-stages. </I>
</P>
<P>
<I>4) We don't agree that a difference in mean age at diagnosis of three years between both treatment arms can be considered to be a pre-selection of older patients. Furthermore, patients diagnosed with cervix carcinoma with effective screening programs are likely to be different from those who present with stage IIIB disease. In addition, we are not aware of any data demonstrating a significant effect of age as predictive factor for treatment outcome following radiotherapy and hyperthermia.</I>
</P>
<P>
<I>5) The Dutch Deep Hyperthermia Trial was started as two separate studies, which were combined into one trial within two years after opening. Although there were differences between the two studies, the primary research question was the same: whether the addition of hyperthermia to radiotherapy improves clinical outcome, and the only difference between the two treatment arms was whether hyperthermia was included in the treatment plan or not.<BR/>
</I>
</P>
<P>
<I>There was a difference in treatment schedules: hyperthermia was given 1 hour after radiotherapy in the Amsterdam study and four hours after radiotherapy in the Rotterdam study. The four hour time interval for the Rotterdam study was not based on logistics, but chosen well-considered. Experimental studies have shown that with a time interval of four hours, there is no risk of increased toxicity, and so no adjustments to radiotherapy were required. Hyperthermia in cancer treatment has multiple effects: direct cell kill, radio and chemosensitisation, changes in blood flow which may influence the sensitivity to radio- and chemotherapy, and anti-cancer immune stimulation. The radiosensitising effect, to which Mr. Roussakow refers, is only part of the effect and still may be present even after a time interval of four hours. </I>
</P>
<P>
<I>Three different hyperthermia systems were used. The performance of these three systems has been compared in a pelvic size phantom, which comparison demonstrated similar energy distributions [1]. Since with all three systems power input during treatment was increased to maximum patient tolerance, there is no reason to assume that the applied hyperthermia treatments differed between the two studies. </I>
</P>
<P>
<I>The numbers of patients in the two separate studies have not been reported. What has been reported is that the overall survival between the two treatment groups differed significantly after adjustment in the regression analysis for age, tumour size, and study/institution. It was further reported that the benefit of hyperthermia was seen in the data analyzed separately from each institution [1,2]</I>
</P>
<P>
<I>6) In the Lancet publication [2], both acute toxicity of hyperthermia, and acute and late toxicity are reported, and the numbers of hyperthermia treatments that the patients received. In the Int J Hyperthermia publication [3], the reasons why patients received fewer than the five planned treatments that were scheduled are reported in more detail. Seven patients received no treatment at all: four refused after initial consent, and in three contraindications were found. Eleven patients had less than four treatments, mostly because refusal. Patients find hyperthermia treatment unpleasant, especially the introduction of the intraluminal thermometry probes and the long duration. The high percentage of patients refusing further treatments probably reflects how well they were informed about the experimental nature of hyperthermia treatment. Since the combination of radiotherapy and hyperthermia became standard treatment for cervical cancer, 93% of the patients received four or five treatments and the main reason for patients receiving fewer than five treatments was logistic difficulties [2].</I>
</P>
<P>
<I>7) As described above we apparently do not agree.</I>
</P>
<P>8) <I>Correct.</I>
</P>
<P>9) <I>The time passed since publication of a study was not limited and hence not an exclusion criterion for inclusion in the analysis. Regarding the quality of both studies the risk of bias analysis is comprehensive in this respect.</I>
</P>
<P>10) <I>This is merely an interpretation, rather than an observation. As stated by Datta et al. &#8220;all cases were randomized and divided into 2 groups&#8221;.</I>
</P>
<P>11) <I>Indeed the number of metastases observed in both groups differed (i.e. 1/23 versus 4/23 patients)although not significantly. Furthermore, outcome measures taken into consideration for the analysis were complete remission rate, local recurrence rate, overall survival and toxicity. We therefore do not agree that this particular information was concealed. </I>
</P>
<P>12) <I>One can argue about the type of trials with the highest evidence level or with most impact on overall effects observed. However, the inherent errors typical for this kind of argument are exactly what the Cochrane review methodology is trying to prevent. Therefore, we prefer to stick to the methods provided by Cochrane. In addition it should be noted that Chen et al do not report survival data in their manuscript. </I>
</P>
<P>13) <I>Taken the data published currently and based on the analysis applying the rules dictated by Cochrane, the authors are convinced that the conclusion as stated is still valid. </I>
</P>
<P/>
<P>
<I>[1] Schneider CJ et al. Quality assurance in various radiative hyperthermia systems applying a phantom with LED matrix. Int J Hyperthermia 1994;10:733-747.</I>
</P>
<P>
<I>[2] Van der Zee J et al. Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomized, multicenter trial. Lancet 2000;355:1119-1125. </I>
</P>
<P>
<I>[3] Van der Zee J and González González. The Dutch Deep Hyperthermia Trial: results in cervical cancer. Int J Hyperthermia 2002;18:1-12.</I>
</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2015-11-26 13:08:52 +0000" MODIFIED_BY="[Empty name]">
<P>Dr Ludy Lutgens on behalf on the author team.</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES MODIFIED="2009-11-10 13:48:02 +0000" MODIFIED_BY="Gail Quinn">
<APPENDIX ID="APP-01" MODIFIED="2009-11-10 13:44:44 +0000" MODIFIED_BY="Gail Quinn" NO="1">
<TITLE MODIFIED="2009-11-09 15:49:58 +0000" MODIFIED_BY="Gail Quinn">MEDLINE</TITLE>
<APPENDIX_BODY MODIFIED="2009-11-10 13:44:44 +0000" MODIFIED_BY="Gail Quinn">
<P>#1 RANDOMIZED-CONTROLLED-TRIAL in PT<BR/>#2 CONTROLLED-CLINICAL-TRIAL in PT<BR/>#3 RANDOMIZED-CONTROLLED-TRIALS<BR/>#4 RANDOM-ALLOCATION<BR/>#5 DOUBLE-BLIND-METHOD<BR/>#6 SINGLE-BLIND-METHOD<BR/>#7 #1 or #2 or #3 or #4 or #5 or #6<BR/>#8 (TG=ANIMALS) not (TG=HUMAN and TG=ANIMALS)<BR/>#9 #7 not #8<BR/>#10 CLINICAL-TRIAL in PT<BR/>#11 explode CLINICAL-TRIALS/ all subheadings<BR/>#12 (clin* near trial*) in TI<BR/>#13 (clin* near trial*) in AB<BR/>#14 (singl* or doubl* or trebl* or tripl*) near (blind* or mask*)<BR/>#15 (#14 in TI) or (#14 in AB)<BR/>#16 PLACEBOS<BR/>#17 placebo* in TI<BR/>#18 placebo* in AB<BR/>#19 random* in TI<BR/>#20 random* in AB<BR/>#21 RESEARCH-DESIGN<BR/>#22 #10 or #11 or #12 or #13 or #15 or #16 or #17 or #18 or #19 or #20 or #21<BR/>#23 (TG=ANIMALS) not (TG=HUMAN and TG=ANIMALS)<BR/>#24 #22 not #23<BR/>#25 #24 not #9<BR/>#26 TG=COMPARATIVE-STUDY<BR/>#27 explode EVALUATION-STUDIES/ all subheadings<BR/>#28 FOLLOW-UP-STUDIES<BR/>#29 PROSPECTIVE-STUDIES<BR/>#30 control* or prospectiv* or volunteer*<BR/>#31 (#30 in TI) or (#30 in AB)<BR/>#32 #26 or #27 or #28 or #29 or #31<BR/>#33 (TG=ANIMALS) not (TG=HUMAN and TG=ANIMALS)<BR/>#34 #32 not #33<BR/>#35 #34 not (#9 or #25)<BR/>#36 #9 or #25 or #35<BR/>#37explode Cervical-Intraepithelial-Neoplasia (MeSH all)<BR/>#38 explode Uterine-Cervical-Neoplasms (MeSH all)<BR/>#39 cervi*<BR/>#40 cancer or tumor or tumour or malignan* or oncol* or carcinom* or neoplas* or growth or adenom* or cyst*<BR/>#41 #39 and #40<BR/>#42 #37 or #38 or #41<BR/>#43 radiother*<BR/>#44 radiat*<BR/>#45 explode Radiotherapy (MeSH all)<BR/>#46 explode Radiotherapy-Computer-Assisted (MeSH all)<BR/>#47 #43 or #44 or #45 or #46<BR/>#48 Hyperther*<BR/>#49 explode Hyperthermia-Induced (MeSH all)<BR/>#50 #48 or #49<BR/>#51 #42 and #47 and #50<BR/>#52 #51and #36</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2009-11-10 13:46:40 +0000" MODIFIED_BY="Gail Quinn" NO="2">
<TITLE MODIFIED="2009-11-09 15:47:34 +0000" MODIFIED_BY="Gail Quinn">EMBASE</TITLE>
<APPENDIX_BODY MODIFIED="2009-11-10 13:46:40 +0000" MODIFIED_BY="Gail Quinn">
<P>#34 #33 and #17<BR/>#33 #32 and #28 and #23<BR/>#32 #31 or #30 or #29<BR/>#31 explode "hyperthermic-therapy" / all SUBHEADINGS in DEM,DER,DRM,DRR<BR/>#30 explode "hyperthermia-" / all SUBHEADINGS in DEM,DER,DRM,DRR<BR/>#29 Hyperther*<BR/>#28 #24 or #25 or #26 or #27<BR/>#27 explode "computer-assisted-radiotherapy" / all SUBHEADINGS in DEM,DER,DRM,DRR<BR/>#26 explode "radiotherapy-" / all SUBHEADINGS in DEM,DER,DRM,DRR<BR/>#25 radiat*<BR/>#24 radiother*<BR/>#23 # 18 or #19 or #20 or #21 or #22<BR/>#22 (cervi*) and (cancer or tumor or tumour or malignan* or oncol* or carcinom* or neoplas* or growth or adenom* or cyst*)<BR/>#21 cancer or tumor or tumour or malignan* or oncol* or carcinom* or neoplas* or growth or adenom* or cyst*<BR/>#20 cervi*<BR/>#19 explode "uterine-cervix-tumor" / all SUBHEADINGS in DEM,DER,DRM,DRR<BR/>#18 explode "uterine-cervix-carcinoma-in-situ" / all SUBHEADINGS in DEM,DER,DRM,DRR<BR/>#17 #12 not #16<BR/>#16 #14 not #15<BR/>#15 #13 and #14<BR/>#14 (ANIMAL or NONHUMAN) in DER<BR/>#13 HUMAN in DER<BR/>#12 #9 or #10 or #11<BR/>#11 (SINGL* or DOUBL* or TREBL* or TRIPL*) near ((BLIND* or MASK*) in TI,AB)<BR/>#10 (RANDOM* or CROSS?OVER* or FACTORIAL* or PLACEBO* or VOLUNTEER*) in TI,AB<BR/>#9 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8<BR/>#8 "SINGLE-BLIND-PROCEDURE"/ all subheadings<BR/>#7 "DOUBLE-BLIND-PROCEDURE"/ all subheadings<BR/>#6 "PHASE-4-CLINICAL-TRIAL"/ all subheadings<BR/>#5 "PHASE-3-CLINICAL-TRIAL"/ all subheadings<BR/>#4 "MULTICENTER-STUDY"/ all subheadings<BR/>#3 "CONTROLLED-STUDY"/ all subheadings<BR/>#2 "RANDOMIZATION"/ all subheadings<BR/>#1 "RANDOMIZED-CONTROLLED-TRIAL"/ all subheadings</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2009-11-10 13:48:02 +0000" MODIFIED_BY="Gail Quinn" NO="3">
<TITLE MODIFIED="2009-11-09 15:48:57 +0000" MODIFIED_BY="Gail Quinn">CENTRAL</TITLE>
<APPENDIX_BODY MODIFIED="2009-11-10 13:48:02 +0000" MODIFIED_BY="Gail Quinn">
<P>#1 Cervical Intraepithelial Neoplasia<BR/>#2 MeSH descriptor Uterine Cervical Neoplasms explode all trees<BR/>#3 cervi*<BR/>#4 cancer or tumor or tumour or malignan* or oncol* or carcinom* or neoplas* or growth or adenom* or cyst*<BR/>#5 (#3 AND #4)<BR/>#6 (#1 OR #2 OR #5)<BR/>#7 radiother*<BR/>#8 radiat*<BR/>#9 MeSH descriptor Radiotherapy explode all trees<BR/>#10 MeSH descriptor Radiotherapy, Computer-Assisted explode all trees<BR/>#11 (#7 OR #8 OR #9 OR #10)<BR/>#12 Hyperther*<BR/>#13 MeSH descriptor Hyperthermia, Induced explode all trees<BR/>#14 (#12 OR #13)<BR/>#15 (#6 AND #11 AND #14)</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>